SPECIAL FEATURE

amplity

OPM ONCOLOGY PRACTICE MANAGEMENT®

FOR ONCOLOGISTS, PRACTICE MANAGERS, FINANCIAL COUNSELORS, AND BILLING/CODING SPECIALISTS™

TWELFTH ANNUAL ONCOLOGY GUIDE TO PATIENT SUPPORT SERVICES

2026 DESK REFERENCE

In partnership with

JONS JOURNAL OF ONCOLOGY NAVIGATION & SURVIVORSHIP

JHOP JOURNAL OF HEMATOLOGY ONCOLOGY PHARMACY

CONNECTING SCIENCE TO PRACTICE

© 2025 Amplity Health

SpringWorks CareConnections™



Not an actual patient.

SpringWorks CareConnections™ provides personalized support services and resources to help your patients get started and stay on track with OGSIVEO® (nirogacestat).

Connections at each point of care

- Coverage and Access Support
- Financial Assistance
- Personalized Educational and Emotional Support
- Field Access Manager (FAM) support

SCAN TO VISIT →

For further information or questions about enrolling your patients, contact

SpringWorks CareConnections

Monday-Friday 8 AM-10 PM ET at **844-CARES-55 (844-227-3755)** or visit **www.springworkstxcares.com/hcp**

SpringWorks THERAPEUTICS

© 2024 SpringWorks Therapeutics, Inc. All rights reserved. C_OGS_US_0408 12/24
OGSIVEO is a registered trademark and SpringWorks CareConnections is a trademark of SpringWorks Therapeutics, Inc.

Ogsiveo® (nirogacestat)
150 mg & 100 mg tablets

amplity

DAWN HOLCOMBE, MBA, FACMPE, ACHE
Editor-at-large

Advertising and Client Solutions
KRISHNA SHAH
Director, Client Partnerships
krishna.shah@amplity.com

Content and Production
BRANDI BRYANT
Editorial Director
brandi.bryant@amplity.com

MANDY KERBEL
Senior Medical Editor

BARBARA MARINO
Senior Medical Editor

BJ HANSEN
Senior Copy Editor

MARIE RS BORRELLI
Senior Production Manager

ALAINA PEDE
Senior Director, Production & Manufacturing

Medical Communications
MELANIE JARDIM, PHD
VP, Strategic Services

KRISTIN SIYAHIAN
VP, Branded Channels

RAMIRO SANDOVAL
VP, Mixed Media

ROBYN JACOBS
Senior Director, Creative & Design

ANTHONY TREVEAN
Senior Director, Digital Services

OPM ONCOLOGY PRACTICE MANAGEMENT®

FOR ONCOLOGISTS, PRACTICE MANAGERS, FINANCIAL COUNSELORS, AND BILLING/CODING SPECIALISTS™

DECEMBER 2025 Special Feature

INTRODUCTION

Connect Your Patients With Critical Resources 7

FEATURED DRUG COMPANY PROGRAMS

AAA Patient Support 8
AbbVie's myAbbVie Assist 10
ADC Therapeutics Advancing Patient Support 10
Amgen SupportPlus 11
Astellas Pharma Support Solutions 15
AstraZeneca Access 360/AZ&Me Prescription Savings Program 16
AVEO ACE 21
Bayer Oncology Support Programs 22
BeiGene Patient Support Services 23
Biocon Biologics Patient Assistance Program 23
Blueprint Medicines Support Services 24
Boehringer Ingelheim CareConnect4Me 24
Bristol Myers Squibb Access Support and Cell Therapy 360 25
Clovis Oncology 32
Coherus Solutions 32
Daiichi-Sankyo Access Central Support Program 33
Daiichi-Sankyo and AstraZeneca Enhertu4U Support Program 35
Deciphera Pharmaceuticals AccessPoint 36
Eisai Patient Support 36
EMD Serono CoverOne Support Services 37
Exelixis Access Services 38
G1 Therapeutics G1 to One Patient Support Program 38
Genentech Oncology My Patient Solutions 39
Genmab Patient Support Services 44
Geron REACH4RYTELO Patient Support Program 44
Gilead Sciences Support Services 45
GSK: Together with GSK Oncology Patient Support Services 46
Helsinn Cares Patient Support Services 47
Immunocore's KIMMTRAK CONNECT 47
ImmunoGen's Elahere Support Services 48
IncyteCARES: Connecting to Access, Reimbursement, Education, and Support 49
IovanceCares Patient Support 50
IPSEN CARES: Coverage, Access, Reimbursement & Education Support 50
JazzCares Patient Support Services 51

Continued on page 4

Oncology Practice Management is included in EBSCO Research Databases.

OPM ONCOLOGY PRACTICE MANAGEMENT®

FOR ONCOLOGISTS, PRACTICE MANAGERS, FINANCIAL COUNSELORS, AND BILLING/CODING SPECIALISTS™

DECEMBER 2025 Special Feature

TABLE OF CONTENTS *(Continued)*

Johnson & Johnson withMe Program 52
Karyopharm KaryForward Patient Support Services 55
Kite Pharma: Kite Konnect 55
Lilly Oncology Support Center 56
MacroGenics' Margenza Access Support 58
Medexus Pharma, Inc. CORE Connections 58
Merck Helps/Merck Access Program 59
Novartis Oncology's Patient Support 64
Nuvation Bio NuvationConnect 69
The Organon Access Program 70
Partner Therapeutics, Inc. PTx Assist 70
Pfizer Oncology Together 71
Pharmacyclics and Johnson & Johnson: Imbruvica By Your Side Patient Support Program 76
Puma Biotechnology Support Services 76
Regeneron's Libtayo Surround Program 77
Rigel Pharmaceuticals Support Services 78
Sandoz One Source Support Services 79
Sanofi CareASSIST Patient Support Services 80
Seagen Secure Support Services 81
Secura Bio Secura Care 82
ServierONE Patient Support Services 83
Sobi's Managed Access Programmes 84
Spectrum Pharmaceutical's Access4Me 84
SpringWorks CareConnections 85
Sun Pharma Patient Support Programs 86
Syndax Pharmaceuticals SyndAccess 86
Taiho Oncology Patient Support Services 87
Takeda Oncology Here2Assist Services 88
TerSera SupportSource 89
Teva Oncology Support Services 90
UroGen Pharma UroGen Support 91
Index by Drug 92

MISSION STATEMENT

Oncology healthcare requires providers to focus attention on financial concerns and strategic decisions that affect the bottom line. To continue to provide the high-quality care that patients with cancer deserve, providers must master the ever-changing business of oncology. *Oncology Practice Management* offers process solutions for members of the cancer care team—medical, surgical, and radiation oncologists, as well as executives, administrators, and coders/billers—to assist them in reimbursement, staffing, electronic health records, REMS, and compliance with state and federal regulations.

Oncology Practice Management (ISSN 2164-4403; USPS Publication # 24780) is published monthly by Amplity, 2050 Cabot Blvd. West, Suite 110, Langhorne, PA 19047. Periodicals postage paid at Langhorne, PA, and at additional mailing offices. POSTMASTER: Send address changes to *Oncology Practice Management*, Circulation Director, 2050 Cabot Blvd. West, Suite 110, Langhorne, PA 19047. © 2025 Amplity, Inc. All rights reserved. *Oncology Practice Management* is a registered trademark of Amplity. No part of this publication may be reproduced or transmitted in any form or by any means now or hereafter known, electronic or mechanical, including photocopy, recording, or any informational storage and retrieval system, without written permission from the Publisher. Printed in the United States of America.

The ideas and opinions expressed in *Oncology Practice Management* do not necessarily reflect those of the Editorial Board, the Editors, or the Publisher. Publication of an advertisement or other product mentioned in *Oncology Practice Management* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturers about any features or limitations of products mentioned. Neither the Editors nor the Publisher assume any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material mentioned in this publication.

EDITORIAL CORRESPONDENCE and permission requests to reprint all or part of any article published in this journal should be emailed to editorial@oncpracticemanagement.com.

Oncology Practice Management is a Member of Alliance for Audited Media

Alliance for Audited Media



Connecting Science to Practice

The ***Journal of Hematology Oncology Pharmacy*** is dedicated to connecting science to practice to provide optimal oncology care for all patients.

Put our expertise to work in your practice by requesting your complimentary print and digital subscriptions.

Scan to subscribe today!

JHOP JOURNAL OF HEMATOLOGY ONCOLOGY PHARMACY

CONNECTING SCIENCE TO PRACTICE™

-Official Peer-Reviewed Publication of-

HOPA Hematology/Oncology Pharmacy Association

visit **JHOPonline.com** to learn more

EDITOR-AT-LARGE

Dawn Holcombe, MBA, FACMPE, ACHE
President DGH Consulting
South Windsor, CT

EDITORIAL BOARD

Carla Balch
President and COO
TransMed Systems
Memphis, TN

Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M, PMI
Practice Management Institute
San Antonio, TX

Vicki Kennedy, LCSW
Vice President
Program Development & Delivery
Cancer Support Community
Washington, DC

Deborah McNeilance, MBA, CMOM, CMIS, CPC, CMC
Practice Management Institute
San Antonio, TX

Bonnie J. Miller, RN, BSN, OCN, FAAMA
Administrative Director
Women's Cancer Center
Fox Chase Cancer Center
Philadelphia, PA

Michael Moore
Vice President Partner
Development, Institutional Development, and Workforce Initiatives
Practice Management Institute
San Antonio, TX

Karna W. Morrow, CPC, RCC, CCS-P, PCS
Senior Consultant
CSI Coding Strategies, Inc
Powder Springs, GA

Ricky Newton, CPA
Treasurer and Director of Financial Services and Operations
Community Oncology Alliance
Director, Cancer Specialists of Tidewater, Ltd
Virginia Beach, VA

Robert D. Orzechowski, MBA, SPHR, SHRM-SCP
Chief Operating Officer
Lancaster Cancer Center
Lancaster, PA

Kashyap Patel, MD
CEO and Managing Partner
Carolina Blood and Cancer Care
Rock Hill, SC

Michael J. Reff, RPh, MBA
President
National Community Oncology Dispensing Association
Ceznovia, NY

Sheryl A. Riley, RN, OCN, CMCN
Chief Nursing Officer
Beacon Advocates
St. Petersburg, FL

Patient Support Services Are Available! Connect Your Patients With Critical Resources

Enroll Your Patients in a Support Program Providing Access to Financial Resources Based on Their Prescribed Treatment

Each year, the publishers of *Oncology Practice Management* update this comprehensive guide to sponsored patient support programs to help you guide your patients to tools and resources that provide more affordable access to their prescribed medications.

The services provided by each company will vary, but most pharmaceutical companies provide patient education about the disease and the prescribed treatment and offer financial assistance for those patients who meet eligibility requirements. Support programs sponsored by pharmaceutical manufacturers may include services such as:

- Copay assistance programs for patients with commercial insurance
- Patient assistance programs for underinsured or uninsured patients
- Medication bridge/temporary access programs
- Dose exchange programs

These services can be of critical help to patients, alleviating some of the anxiety and financial pressures that patients experience when dealing with a cancer diagnosis. In addition to patient support, there are also services to help you and your office staff, such as benefit verification, insurance coverage determination, prior authorizations, and claims/appeals support.

This *Guide* organizes patient support programs by company name and lists the services each company offers for each drug. A list by drug name is included in the index.

We encourage all oncology healthcare providers to use the *Guide* and share this information with patients. We hope the *Guide* proves to be a useful tool to you in your practice.

EDITOR'S NOTE: The company profiles in this *Guide* are based on information posted online by the respective pharmaceutical companies as of November 6, 2025. Every effort has been made to verify the information up to that time. Any updates, including new drugs approved after that time, will not appear in this publication, but they will be added to the *Guide* on the *Oncology Practice Management* website. The Publisher and the Editors are not responsible for any inaccuracies stemming from changes, new drug approvals, or company updates that became available later. Readers are advised to review the websites of each drug company for any updates and revisions.

AAA Patient Support

www.pluvicto-hcp.com/psma-positive-mcrpc/novartis-patient-support
www.lutathera-hcp.com/novartis-patient-support

Advanced Accelerator Applications (AAA), a Novartis Company, offers programs to deliver assistance to eligible patients who have been prescribed Pluvicto or Lutathera. ◆

AAA Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) injection	Treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy; treatment of pediatric patients aged ≥12 years with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors	Novartis Patient Support	www.pluvicto-hcp.com/psma-positive-mcrpc/novartis-patient-support
		The Novartis Patient Assistance Foundation	www.pap.novartis.com/ 800-277-2254
Lutathera (lutetium Lu 177 dotatate) injection for intravenous use	Treatment of adult and pediatric patients aged ≥12 years with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors	Novartis Patient Support	www.lutathera-hcp.com/novartis-patient-support
		The Novartis Patient Assistance Foundation	www.pap.novartis.com/ 800-277-2254

Genmab

Patient Support at Your *Fingertips*



MyNavCare®
PATIENT SUPPORT BY GENMAB

Arm your patients with support and resources as they navigate treatment with a Genmab medication

MyNavCare Patient Support by Genmab® offers services to assist your patients on their treatment journey.

To enroll patients, visit **MyNavCare.com**

For more information, call **1-866-NAV-CAR1** (1-866-628-2271).

*Based on eligibility requirements and Terms and Conditions.

†*MyNavCare* Patient Engagement Liaisons are part of the *MyNavCare Patient Support by Genmab* Program and do not provide medical advice or work under the direction of the prescribing healthcare providers. They are trained to direct patients to speak with their HCP about any treatment-related questions. *MyNavCare Patient Support by Genmab* is a trademark of Genmab A/S. © 2025 Genmab A/S. All rights reserved.

10/2025 COM-US-UNB-0000885

AbbVie's MyAbbVie Assist

888-249-4918
www.venclextahcp.com/cll/financial-support/assistance-options.html
www.venclexta.com/previously-untreated-cll/ven-zone-signup

AbbVie offers the **myAbbVie Assist** program to support patients who have been prescribed an AbbVie drug. ◆

AbbVie Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Emrelis (telisotuzumab vedotin-tllv)	Treatment of adults with locally advanced or metastatic, nonsquamous non–small cell lung cancer with high c-Met protein overexpression (≥50% of tumor cells with strong [3+] staining), as determined by an FDA-approved test, who have received a prior systemic therapy	Patient Access Support	www.abbvie.com/content/dam/abbvie-com2/pdfs/pap/emrelis-application.pdf 844-900-2228
Venclexta (venetoclax)	Treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma; treatment, in combination with azacitidine, or decitabine, or low-dose cytarabine, of newly diagnosed acute myeloid leukemia in patients aged ≥75 years, or those who have comorbidities that preclude use of intensive induction chemotherapy	Venclexta Access Solutions	www.venclextahcp.com/cll/financial-support/assistance-options.html www.venclexta.com/previously-untreated-cll/ven-zone-signup 888-249-4918
		Genentech Oncology Co-pay Assistance Program	www.venclextahcp.com/cll/financial-support/assistance-options.html#copaycard
		Genentech Patient Foundation	www.venclextahcp.com/cll/financial-support/assistance-options.html#patientfoundation

ADC Therapeutics Advancing Patient Support

855-690-0340
www.advancingpatientsupport.com/hcp/

ADC Therapeutics offers the **Advancing Patient Support** program to assist patients and their healthcare providers access to Zynlonta. ◆

ADC Therapeutics Oncology Drug

Drug	Indication	Patient support programs	Contact information
Zynlonta (loncastuximab tesirine-lpyl) for injection	Treatment of adult patients with relapsed or refractory large B-cell lymphoma after ≥2 lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma	Copay Assistance Program Patient Assistance Program	www.advancingpatientsupport.com/hcp/ 855-690-0340

Amgen SupportPlus

866-264-2778
www.amgensupportplus.com

Amgen offers assistance to patients through **Amgen SupportPlus Co-Pay Program** and the **Amgen Safety Net Foundation**. Patients can register for this program by visiting **www.amgensupportplus.com**. ◆

Amgen Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Aranesp (darbepoetin alfa)	To treat the effects of concomitant myelosuppressive chemotherapy; on initiation, a minimum of 2 additional months of chemotherapy are planned	Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Blincyto (blinatumomab)	Treatment of adult and pediatric patients with: CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease ≥0.1%; treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia; treatment of adult and pediatric patients aged ≥1 month with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase, regardless of measurable residual disease status	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Epogen (epoetin alfa)	To treat the effects of concomitant myelosuppressive chemotherapy; upon initiation, there is a minimum of 2 additional months of planned chemotherapy	Amgen SupportPlus Co-Pay Program	www.amgenesas.com/Support-and-Services 866-264-2778
Imdelltra (tarlatamab-dlle)	Treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Imlygic (talimogene laherparepvec)	Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Kanjinti (trastuzumab-anns)	Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma; select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778

Amgen SupportPlus... *(Continued)*

Amgen Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Kyprolis (carfilzomib)	Treatment of adult patients with relapsed or refractory multiple myeloma after 1 to 3 lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone; monotherapy for relapsed or refractory multiple myeloma who have received ≥1 line of therapy	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Lumakras (sotorasib)	Treatment of adult patients with *KRAS* G12C–mutated locally advanced or metastatic non–small cell lung cancer, as determined by an FDA-approved test, who have received ≥1 prior systemic therapy; treatment of adults with *KRAS* G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Mvasi (bevacizumab-awwb)	Treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. • Unresectable, locally advanced, recurrent or metastatic nonsquamous non–small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. • Recurrent glioblastoma in adults. • Metastatic renal cell carcinoma in combination with interferon-alfa. • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: ◦ in combination with carboplatin and paclitaxel, followed by Mvasi as a single agent, for stage III or IV disease following initial surgical resection	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778

Amgen SupportPlus... *(Continued)*

Amgen Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Mvasi (bevacizumab-awwb) *(cont)*	◦ in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received ≤2 prior chemotherapy regimens ◦ in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Mvasi as a single agent, for platinum-sensitive recurrent disease		
Neulasta (pegfilgrastim)	To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
Neupogen (filgrastim)	To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever; to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia; to reduce the duration of neutropenia and neutropenia-related clinical sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation; to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
Nplate (romiplostim)	Treatment of adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; treatment of pediatric patients ≥1 year of age with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778

Amgen SupportPlus... *(Continued)*

Amgen Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Prolia (denosumab)	Increase bone mass (1) in men with prostate cancer receiving androgen-deprivation therapy, or (2) in women with breast cancer receiving adjuvant aromatase inhibitor therapy	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Riabni (rituximab-arrx)	Treatment of: Adult patients with non-Hodgkin lymphoma (NHL), including relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy; in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; nonprogressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens; treatment of adult patients with chronic lymphocytic leukemia (CLL), including previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
Vectibix (panitumumab)	Treatment of wild-type *RAS* metastatic colorectal cancer as either first-line in combination with FOLFOX or as monotherapy following disease progression after prior treatment with chemotherapy	Amgen SupportPlus Co-Pay Program	wwww.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778
Xgeva (denosumab)	To prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity; treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy	Amgen SupportPlus Co-Pay Program	www.amgensupportplus.com/copay-program 866-264-2778
		Amgen Safety Net Foundation	www.amgensafetynetfoundation.com 866-264-2778

Astellas Pharma Support Solutions

www.astellaspharmasupportsolutions.com

Astellas Pharma's **Support Solutions** offers access and reimbursement support to help eligible patients overcome challenges to accessing Astellas products. ◆

Astellas Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Padcev (enfortumab vedotin-ejfv) for injection	Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received ≥1 line of therapy In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer	Padcev Copay Assistance Program	www.astellaspharmasupportsolutions.com/products/padcev/patient_assistance/padcev_copay_assistance_program.aspx 888-402-0627
		Padcev Patient Assistance Program	www.astellaspharmasupportsolutions.com/products/padcev/patient_assistance/patient_assistance_program.aspx 888-402-0627
Vyloy (zolbetuximab-clzb)	In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN 18.2 positive as determined by an FDA-approved test	Vyloy Copay Assistance Astellas Patient Assistance Program	www.vyloysupportsolutions.com/ 855-272-6609
Xospata (gilteritinib) tablets	Treatment of adults with relapsed or refractory acute myeloid leukemia and an *FLT3* mutation, as detected by an FDA-approved test	Xospata Patient Savings Program	www.astellaspharmasupportsolutions.com/products/xospata/patient_assistance/xospata_patient_savings_program.aspx 855-221-3493
		Astellas Patient Assistance Program	www.astellaspharmasupportsolutions.com/products/xospata/patient_assistance/astellas_patient_assistance_program.aspx 844-632-9272
		Xospata QUICK START+ Program	www.astellaspharmasupportsolutions.com/products/xospata/quick_start.aspx
Xtandi (enzalutamide) capsules	Treatment of castration-resistant prostate cancer; metastatic castration-sensitive prostate cancer	Xtandi Patient Savings Program	www.astellaspharmasupportsolutions.com/products/xtandi/patient_assistance/xtandi_patient_savings_program.aspx 855-217-8311
		Astellas Patient Assistance Program	www.astellaspharmasupportsolutions.com/products/xtandi/patient_assistance/astellas_patient_assistance_program.aspx 855-898-2634
		Xtandi QUICK START+ Program	www.astellaspharmasupportsolutions.com/products/xtandi/quick_start.aspx

AstraZeneca Access 360/AZ&Me Prescription Savings Program

AstraZeneca Access 360
844-275-2360
www.myaccess360.com

AZ&Me Prescription Savings Program
800-292-6363
www.azandmeapp.com

AstraZeneca, through its **Access 360** and **AZ&Me** programs, offers a range of patient assistance to help streamline access and reimbursement for select AstraZeneca medicines. ◆

AstraZeneca Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Calquence (acalabrutinib)	• Treatment of mantle cell lymphoma after ≥1 previous therapies. • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation. • Treatment of adults with chronic lymphocytic leukemia or with small lymphocytic lymphoma.	AstraZeneca Access 360	www.myaccess360.com/calquence-acalabrutinib/our-services.html
		Calquence Co-pay Savings Program	www.myaccess360.com/calquence-acalabrutinib/patient-affordability.html
		AZ&Me Prescription Savings Program	www.azandmeapp.com

Enhertu (fam-trastuzumab deruxtecan-nxki)	Treatment of:
	• Adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+ or in situ hybridization [ISH] positive) breast cancer who have received a prior anti-HER2-based regimen, either:
	  • in the metastatic setting, or
	  • in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
	• Adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH negative) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
	• Adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have activating *HER2 (ERBB2)* mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
	• Adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
	• Adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
		AstraZeneca Access 360	www.myaccess360.com/our-services.html

		Patient Savings Program Patient Assistance Program	www.enhertu4u.com/hcp/affordability.html 833-364-3788

Continued on page 18

REACH4 RYTELO®

Providing patient access and reimbursement support after RYTELO is prescribed



Benefits Investigation



Prior Authorization



Appeals Support



Patient Affordability Programs

All programs provided through REACH4RYTELO are subject to eligibility requirements. Geron reserves the right to modify or discontinue REACH4RYTELO at any time without notice. The accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. REACH4RYTELO and its agents make no guarantee regarding coverage and reimbursement for RYTELO.

Getting Started

If you determine RYTELO is right for your patient, download the REACH4RYTELO Patient Enrollment Form at www.reach4rytelo.com.

Complete the form with your patient and submit via fax or email. A completed form includes signatures from both the patient and the healthcare provider.



Fax: 1-888-224-2518



Email: Support@REACH4RYTELO.com



For more information about REACH4RYTELO, call **1-844-4RYTELO (1-844-479-8356)** Monday through Friday, 8 AM to 5 PM ET, or visit www.reach4rytelo.com.

geron®

RYTELO® (imetelstat) for Injection 47 mg 188 mg

©2025 Geron Corp. All rights reserved.
GERON, GERON logo, RYTELO, RYTELO logo, and REACH4RYTELO are registered trademarks of Geron Corporation.

C-US-RYT-IM-0210 v3 November 2025

AstraZeneca Access 360/AZ&Me... *(Continued)*

AstraZeneca Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Faslodex (fulvestrant)	Treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy; HR-positive advanced breast cancer in postmenopausal women whose disease progressed after endocrine therapy; in combination with palbociclib or abemaciclib, for HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy; HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine-based therapy or following disease progression on endocrine therapy	AstraZeneca Access 360	www.myaccess360.com/faslodex-fulvestrant/our-services.html
		Faslodex Co-pay Savings Program	www.myaccess360.com/faslodex-fulvestrant/patient-affordability.html
Imfinzi (durvalumab)	• In combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by Imfinzi continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥4 cm and/or node positive) non–small cell lung cancer (NSCLC) and no known *EGFR* mutations or *ALK* rearrangements. • As a single agent, for the treatment of adult patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. • In combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing *EGFR* mutations or *ALK* genomic tumor aberrations. • In combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (SCLC). • In combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer. • In combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma. • In combination with carboplatin and paclitaxel followed by Imfinzi as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient. • As a single agent, for the treatment of adult patients with limited-stage SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. • In combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer.	AstraZeneca Access 360	www.myaccess360.com/imfinzi-durvalumab.html
		Imfinzi Co-pay Savings Program	www.myaccess360.com/imfinzi-durvalumab/patient-affordability.html
		AZ&Me Prescription Savings Program	www.azandmeapp.com

AstraZeneca Access 360/AZ&Me... *(Continued)*

AstraZeneca Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Imjudo (tremelimumab-actl)	In combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma; in combination with durvalumab and platinum-based chemotherapy for the treatment of adults with metastatic NSCLC with no sensitizing *EGFR* mutations or *ALK* genomic tumor aberrations	AstraZeneca Access 360	www.myaccess360.com/imfinzi-durvalumab.html
		Imjudo Co-pay Savings Program	www.myaccess360.com/imfinzi-durvalumab/patient-affordability.html
		AZ&Me Prescription Savings Program	www.azandmeapp.com
Iressa (gefitinib)	First-line treatment of metastatic NSCLC with *EGFR* exon 19 deletions or exon 21 (L858R) substitution mutations, as determined by an FDA-approved test	AstraZeneca Access 360	www.myaccess360.com/iressa-gefitinib/our-services.html
Lynparza (olaparib)	In select patients as determined by an FDA-approved diagnostic for Lynparza, maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic *BRCA*-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency-positive status defined by either: a deleterious or suspected deleterious *BRCA* mutation, and/or genomic instability; maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, adjuvant treatment of adult patients with deleterious or suspected deleterious g*BRCA*m HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, treatment of adult patients with deleterious or suspected deleterious g*BRCA*m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor–positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy; in select patients as determined by an FDA-approved diagnostic for Lynparza, maintenance treatment of adult patients with deleterious or suspected deleterious g*BRCA*m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; in select	AstraZeneca Access 360	www.myaccess360.com/lynparza-olaparib/our-services.html
		Lynparza Co-pay Savings Program	www.myaccess360.com/lynparza-olaparib/patient-affordability.html
		AZ&Me Prescription Savings Program	www.azandmeapp.com

AstraZeneca Access 360/AZ&Me... *(Continued)*

AstraZeneca Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Lynparza (olaparib) *(cont)*	patients as determined by an FDA-approved diagnostic for Lynparza, treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide or abiraterone; in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious *BRCA*m metastatic castration-resistant prostate cancer based on an FDA-approved companion diagnostic for Lynparza		
Tagrisso (osimertinib)	Adjuvant treatment after tumor resection in adult patients with non–small cell lung cancer (NSCLC) and *EGFR* exon 19 deletions or exon 21 L858R mutations; first-line treatment of adult patients with metastatic NSCLC and *EGFR* exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test; treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test; treatment of NSCLC with *EGFR* T790 mutation, as determined by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy; in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test	AstraZeneca Access 360	www.myaccess360.com/tagrisso-osimertinib/our-services.html
		Tagrisso Co-pay Savings Program	www.myaccess360.com/tagrisso-osimertinib/patient-affordability.html
		AZ&Me Prescription Savings Program	www.azandmeapp.com

AVEO ACE

833-368-4832
www.fotivdahcp.com/access-support/

AVEO Pharmaceuticals offers **AVEO ACE**, a comprehensive program dedicated to providing personalized support to patients and their caregivers while taking Fotivda treatment. ◆

AVEO Pharmaceuticals Oncology Drug

Drug	Indication	Patient support programs	Contact information
Fotivda (tivozanib) capsules, for oral use	Treatment of adult patients with relapsed or refractory advanced renal cell carcinoma following ≥2 prior systemic therapies	AVEO ACE	www.fotivdahcp.com/access-support/aveo-ace/#FinancialAssistance 833-368-4832
		Quick Start Program/ Bridge Program	www.fotivdahcp.com/access-support/aveo-ace/#FinancialAssistance 833-368-4832
		AVEO ACE Co-pay Assistance Program	www.fotivdahcp.com/access-support/financial-assistance/ 833-368-4832
		AVEO ACE Patient Assistance Program	www.fotivdahcp.com/access-support/aveo-ace/#FinancialAssistance 833-368-4832

Bayer Oncology Support Programs

866-228-7723
www.patientassistance.bayer.us/en/resources

800-288-8374
Access Services by Bayer

Bayer offers drug-specific programs to assist patients with access and resources. A complete list of Bayer oncology products and their related assistance programs is provided in the **Table**. ◆

Bayer Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Nubeqa (darolutamide)	Treatment of adults with nonmetastatic castration-resistant prostate cancer; treatment of adults with metastatic castration-sensitive prostate cancer (mCSPC); and treatment of adutls with mCSPC in combination with docetaxel	Access Services by Bayer	www.nubeqahcp.com/access-and-support/access-services-by-bayer
		Nubeqa $0 Co-Pay Program	www.nubeqacopayprogram.com
		Bayer US Patient Assistance Foundation	www.patientassistance.bayer.us/en/resources
Stivarga (regorafenib)	Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if *RAS* wild-type, an anti-EGFR therapy; treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor who have been previously treated with imatinib mesylate and sunitinib malate; patients with hepatocellular carcinoma who have been previously treated with sorafenib	Access Services by Bayer	www.hcp.stivarga-us.com/access-services-by-bayer
		Stivarga $0 Co-Pay Program	www.zerocopaysupport.com/stivarga
		Bayer US Patient Assistance Foundation	www.patientassistance.bayer.us/en/resources
Vitrakvi (larotrectinib)	Treatment of adult and pediatric patients with solid tumors that have an *NTRK* gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or who have progressed following treatment, based on an FDA-approved test	Access Services by Bayer	www.hcp.vitrakvi-us.com/support-and-resources/access
		Bayer US Patient Assistance Foundation	www.patientassistance.bayer.us/en/resources
Xofigo (radium Ra 223 dichloride) injection	Treatment of castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease	Xofigo Access Services	www.xofigo-us.com/patient/xofigo-support/ 855-696-3446

BeiGene Patient Support Services

833-234-4363
www.mybeonesupport.com/brukinsa/hcp/

BeiGene offers the **myBeOne Support Program** to provide appropriate information and assistance to patients taking Brukinsa. ◆

BeiGene Oncology Drug

Drug	Indications	Patient support programs	Contact information
Brukinsa (zanubrutinib) capsules	Treatment of adults with mantle cell lymphoma after ≥1 previous therapy; treatment of adult patients with Waldenström's macroglobulinemia; treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received ≥1 anti-CD20-based regimen; treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma; treatment of relapsed or refractory follicular lymphoma, in combination with obinutuzumab, after ≥2 lines of systemic therapy	Co-pay Support Program	www.mybeonesupport.com/brukinsa/hcp/program-services/#copay-support
		Free Product Assistance Program	www.mybeonesupport.com/brukinsa/hcp/program-services/#free-product
		Bridge Supply	www.mybeonesupport.com/brukinsa/hcp/program-services/#bridge-supply

Biocon Biologics Patient Assistance Program

844-224-6266
www.bioconbiologicsus.com/pap

Biocon Biologics offers the **Biocon Biologics Patient Assistance Program** to provide continuous access and support to patients who have been prescribed Fulphila or Ogivri. ◆

Biocon Biologics Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Fulphila (pegfilgrastim-jmdb)	To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia	Co-pay Assistance Patient Assistance	www.fulphila.com/ 833-695-2623
Ogivri (trastuzumab-dkst)	Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product	Co-pay Assistance Patient Assistance	www.ogivrihcp.com 833-695-2623

Blueprint Medicines Support Services

888-258-7768
www.yourblueprint.com/hcp

Blueprint Medicines offers the **YourBlueprint** patient support program to provide appropriate information and assistance to patients taking Ayvakit. ◆

Blueprint Oncology Drug

Drug	Indications	Patient support programs	Contact information
Ayvakit (avapritinib) tablets	Treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a *PDGFRA* exon 18 mutation, including *PDGFRA* D842V mutations; treatment of adult patients with advanced systemic mastocytosis to include aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast-cell leukemia; treatment of adult patients with indolent systemic mastocytosis	QuickStart Program Coverage Interruption Program Ayvakit Dose Exchange Program	www.yourblueprint.com/hcp/temporary-access/ 888-258-7768
		Co-Pay Assistance Program Patient Assistance Program	www.yourblueprint.com/hcp/financial-assistance/ 888-258-7768

Boehringer Ingelheim CareConnect4Me

800-556-8317
https://pro.boehringer-ingelheim.com/us/care-connect/

Boehringer Ingelheim offers the **CareConnect4Me** program to provide appropriate information and assistance to patients receiving Gilotrif or Hernexeos. ◆

Boehringer Ingelheim Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Gilotrif (afatinib)	First-line treatment of metastatic non–small cell lung cancer (NSCLC) with nonresistant *EGFR* mutations, as detected by an FDA-approved test; treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy	Co-pay Assistance Program Bridge Program Gilotrif Dose Exchange Program	https://pro.boehringer-ingelheim.com/us/products/gilotrif/starting-your-patient
		BI Cares Patient Assistance Program	www.boehringer-ingelheim.com/us/about-us/sustainable-development/our-commitment/boehringer-cares-patient-assistance-portal 800-556-8317
Hernexeos (zongertinib)	Treatment of adult patients with unresectable or metastatic non-squamous non–small cell lung cancer whose tumors have HER2 (*ERBB2*) tyrosine kinase–domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy	Copay Assistance	https://patient.boehringer-ingelheim.com/us/products/hernexeos/support-and-saving 855-297-5903

Bristol Myers Squibb Access Support and Cell Therapy 360

800-861-0048
www.bmsaccesssupport.com

800-736-0003
www.bmspaf.org

888-805-4555
www.celltherapy360.com/hcp

Bristol Myers Squibb (BMS) offers the **Access Support**, **Patient Assistance Foundation**, and **Cell Therapy 360** programs for patients prescribed a BMS medication. ◆

BMS Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Abecma (idecabtagene vicleucel) suspension for intravenous infusion	Treatment of adult patients with relapsed or refractory multiple myeloma after ≥4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody	Cell Therapy 360	www.abecmahcp.com/abecma-support/ 888-805-4555
Abraxane (paclitaxel protein-bound particles) for injectable suspension	Treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse ≤6 months of adjuvant chemotherapy; locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin; metastatic pancreatic cancer, in combination with gemcitabine	BMS Access Support Co-Pay Assistance Program	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Access Support Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Augtyro (repotrectinib) capsules	Treatment of adult patients with locally advanced or metastatic *ROS1*-positive non–small cell lung cancer; treatment of adult and pediatric (aged ≥12 years) patients with solid tumors that have *NTRK* gene fusion and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and who have progressed following treatment or have no satisfactory alternative therapy	BMS Access Support	www.augtyrohcp.com/access-support 800-861-0048
Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion	Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B, who have: • refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or • refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age; or • relapsed or refractory disease after ≥2 lines of systemic therapy	Cell Therapy 360	www.breyanzi.com/support/cell-therapy-360 888-805-4555

Bristol Myers Squibb Access... *(Continued)*

BMS Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Empliciti (elotuzumab) for injection	Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received 1 to 3 prior therapies; treatment of multiple myeloma in combination with pomalidomide and dexamethasone in adult patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor	BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Idhifa (enasidenib) tablets	Treatment of adult patients with relapsed or refractory acute myeloid leukemia associated with *IDH2* mutation, as detected by an FDA-approved test	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Inrebic (fedratinib)	Treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Onureg (azacitidine) tablets	Continued treatment of adults with acute myeloid leukemia who achieved first complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and are not able to complete intensive curative therapy	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003

Bristol Myers Squibb Access... *(Continued)*

BMS Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Opdivo (nivolumab)	Treatment of adult and pediatric (aged ≥12 years) patients with unresectable or metastatic melanoma as a single agent or in combination with ipilimumab; treatment of adult and pediatric (aged ≥12 years) patients with melanoma with involvement of lymph nodes or metastatic disease in patients who have undergone complete resection Neoadjuvant treatment of adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥4 cm and/or node positive) NSCLC and no known *EGFR* mutations or *ALK* rearrangements; in combination with ipilimumab, for first-line treatment of metastatic NSCLC in adult patients whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test with no *EGFR* or *ALK* genomic tumor aberrations; treatment of adult patients in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy as first-line treatment of metastatic or recurrent NSCLC with no *EGFR* or *ALK* genomic tumor aberrations; treatment of adult patients with metastatic NSCLC with progression on or after platinum-based chemotherapy; patients with *EGFR* or *ALK* genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo First-line treatment of adult patients with unresectable malignant pleural mesothelioma in combination with ipilimumab First-line treatment of adult patients with intermediate or poor-risk advanced renal cell carcinoma (RCC) in combination with ipilimumab; first-line treatment of adult patients with advanced RCC in combination with cabozantinib; treatment of adult patients with advanced RCC who have received prior antiangiogenic therapy Treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after either autologous hematopoietic stem cell transplant (HSCT) and brentuximab vedotin or ≥3 lines of systemic therapy that includes autologous HSCT Treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy First-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC) in combination with cisplatin and gemcitabine; adjuvant treatment of adult patients with UC who are at high risk for recurrence after undergoing radical resection; treatment of adult patients	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003

Bristol Myers Squibb Access... *(Continued)*

BMS Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Opdivo (nivolumab) *(cont)*	with locally advanced or metastatic UC who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Treatment of adult and pediatric (aged ≥12 years) patients, administered as a single agent or in combination with ipilimumab, with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; with ipilimumab, treatment of adult and pediatric patients (aged ≥12 years) with unresectable or metastatic MSI-H or dMMR CRC Treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib in combination with ipilimumab; first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma Adjuvant treatment of adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy; treatment of adults with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-containing chemotherapy Treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy		
Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)	Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC), as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab; treatment of adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib; treatment of adult patients with advanced RCC who have received prior antiangiogenic therapy Treatment of adult patients with unresectable or metastatic melanoma; treatment of adult patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab Adjuvant treatment of adult patients with completely resected stage IIB, stage IIC, stage III, or stage IV melanoma	BMS Access Support BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/ 800-861-0048 www.bmscopay.com/ www.bmsaccesssupport.com/co-pay-financial-assistance 800-861-0048

Bristol Myers Squibb Access... *(Continued)*

BMS Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) *(cont)*	Treatment of adult patients with resectable (tumors ≥4 cm or node positive) non–small cell lung cancer (NSCLC) in the neoadjuvant setting, in combination with platinum-doublet chemotherapy; treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known *EGFR* mutations or *ALK* rearrangements, for neoadjuvant treatment, in combination with platinum doublet chemotherapy, followed by Opdivo Qvantig monotherapy as adjuvant treatment after surgery; treatment of adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy Treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on squamous cell or after a platinum-based therapy Adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC; treatment of adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine; treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy, or • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy or as monotherapy following combination treatment with intravenous nivolumab and ipilimumab Treatment of adult patients with hepatocellular carcinoma previously treated with sorafenib and following combination treatment with intravenous nivolumab and ipilimumab Treatment of adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy; treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1); treatment of adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy Treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy		

Bristol Myers Squibb Access... *(Continued)*

BMS Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Opdualag (nivolumab and relatlimab-rmbw) injection	Treatment of adult and pediatric (aged ≥12 years) patients with unresectable or metastatic melanoma	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Pomalyst (pomalidomide)	Treatment of adult patients with multiple myeloma, in combination with dexamethasone, after ≥2 therapies, including lenalidomide and a proteasome inhibitor, whose disease progressed during or within 60 days of completing the last therapy. Treatment of adult patients with with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Reblozyl (luspatercept-aamt)	Treatment of: • anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions • anemia in adult patients without previous erythropoiesis-stimulating agent use and with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular RBC transfusions • anemia in adult patients who responded inadequately to an erythropoiesis-stimulating agent and requiring ≥2 RBC units over 8 weeks and with very low- to intermediate-risk MDS with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Revlimid (lenalidomide) capsules	Treatment of adult patients with: multiple myeloma, in combination with dexamethasone or as maintenance after autologous hematopoietic stem cell transplant; transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q; mantle cell lymphoma in patients whose disease relapsed or progressed after 2 therapies, including bortezomib; previously treated follicular lymphoma, in combination with rituximab-containing therapy; previously treated marginal-zone lymphoma, in combination with rituximab-containing therapy	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003

Bristol Myers Squibb Access... *(Continued)*

BMS Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Sprycel (dasatinib)	Treatment of: • newly diagnosed adults with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib • adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy • pediatric patients aged ≥1 year with Ph+ CML in chronic phase • pediatric patients aged ≥1 year with newly diagnosed Ph+ ALL in combination with chemotherapy	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Thalomid (thalidomide)	Treatment of patients with newly diagnosed multiple myeloma in combination with dexamethasone	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003
Yervoy (ipilimumab)	Treatment of unresectable or metastatic melanoma in patients ≥12 years; treatment of unresectable or metastatic melanoma in adult patients in combination with nivolumab; adjuvant treatment of patients with cutaneous melanoma and involvement of regional lymph nodes >1 mm after complete resection, including total lymphadenectomy. First-line treatment of intermediate- or poor-risk advanced renal cell carcinoma, in combination with nivolumab. Treatment of patients ≥12 years with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer progressing after fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab. Treatment of hepatocellular carcinoma after sorafenib therapy, in combination with nivolumab. First-line treatment of metastatic non–small cell lung cancer (NSCLC) expressing PD-L1 (≥1%), as determined by an FDA-approved test, and no *EGFR* or *ALK* genomic tumor aberrations, in combination with nivolumab; first-line treatment, in combination with 2 cycles of platinum-doublet chemotherapy and nivolumab, of metastatic or recurrent NSCLC with no *EGFR* or *ALK* genomic tumor aberrations. First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, in combination with nivolumab	BMS Access Support	www.bmsaccesssupport.com/enrollment 800-861-0048
		BMS Oncology Co-Pay Assistance Program	www.bmsaccesssupport.com/co-pay-financial-assistance
		BMS Patient Assistance Foundation	www.bmspaf.org 800-736-0003

Clovis Oncology

844-779-7717
www.rubracahcp.com/

Clovis Oncology offers several programs to assist patients who have been prescribed Rubraca. ◆

Clovis Oncology Drug

Drug	Indications	Patient support programs	Contact information
Rubraca (rucaparib) tablets	Maintenance treatment of adults with a deleterious *BRCA* mutation (germline and/or somatic) associated with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; treatment of adults with a deleterious *BRCA* mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca	Rubraca Co-pay Program QuickStart Program Patient Assistance Program Coverage Link Program	www.rubracahcp.com/ 844-779-7707

Coherus Solutions

844-483-3692
www.coherussolutions.com/udenyca/healthcare-professionals

Coherus BioSciences' **Coherus Solutions** offers comprehensive reimbursement and support services for patients receiving treatment with **Udenyca** (pegfilgrastim-cbqv) who are unable to afford this medication. The program also offers provider coding and billing services to facilitate appropriate billing and reimbursement. ◆

Coherus BioSciences Oncology Drug

Drug	Indication	Patient support program	Contact information
Udenyca (pegfilgrastim-cbqv)	Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)	Co-Pay Savings Program	www.coherussolutions.com/udenyca/financial-assistance/commercial 844-483-3692

Daiichi-Sankyo Access Central Support Program

866-437-4669
www.daiichisankyo.us/patient-assistance-programs

Daiichi-Sankyo's **Access Central** offers comprehensive reimbursement and support services for patients who are prescribed a Daiichi-Sankyo medicine. ◆

Daiichi-Sankyo Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Datroway (datopotamab deruxtecan-dlnk)	Treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy; treatment of adult patients with unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease	Patient Savings Program Patient Assistance Program	www.datrowayhcp.com/support-resources/access-support 855-328-7648
Enhertu (fam-trastuzumab deruxtecan-nxki) for injection	Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy; treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-low, or HER2-ultralow breast cancer, that has progressed on >1 endocrine therapies in the metastatic setting, as determined by an FDA-approved test; treatment of adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy; treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen; treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options	Enhertu4U	www.enhertu4u.com/hcp.html 833-364-3788
		Patient Savings Program Patient Assistance Program	www.enhertu4u.com/hcp/affordability.html 833-364-3788

Daiichi-Sankyo Access Central Support... *(Continued)*

Daiichi-Sankyo Oncology/Supportive Care Drugs			
Drugs	**Indications**	**Patient support programs**	**Contact information**
Injectafer (ferric carboxymaltose injection)	Treatment of iron-deficiency anemia in adults and pediatric patients ≥1 year of age who are intolerant to or have had an unsatisfactory response to oral iron replacement therapy; treatment of adults with non-dialysis-dependent chronic kidney disease; treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity	Injectafer Savings Program	www.injectafercopay.com
		Injectafer Patient Assistance Program	www.dsiaccesscentral.com/hcp/injectafer/financial-help/pap 866-437-4669
Turalio (pexidartinib) capsules	Treatment of adult patients with symptomatic tenosynovial giant-cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery	Turalio QuickStart Program	www.dsiaccesscentral.com/hcp/turalio/coverage-access/quickstart
		Turalio Copay Program	www.dsiaccesscentral.com/hcp/turalio/financial-help/copay
		Turalio Patient Assistance Program	www.dsiaccesscentral.com/hcp/turalio/financial-help/pap 866-437-4669
Vanflyta (quizartinib)	Treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication–positive, as detected by an FDA-approved test; to be given with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy	Access Central Patient Support	www.vanflytahcp.com/en/resources
		Vanflyta Savings Program	www.dsiaccesscentral.com/hcp/vanflyta-/financial-help/savings 866-437-4669
		Vanflyta Patient Assistance Program	www.dsiaccesscentral.com/hcp/vanflyta/financial-help/pap 866-437-4669
		Vanflyta QuickStart Program	www.dsiaccesscentral.com/hcp/vanflyta/coverage-access/quickstart 866-437-4669

Daiichi-Sankyo and AstraZeneca Enhertu4U Support Program

833-364-3788
www.enhertu4u.com/hcp.html

Daiichi-Sankyo and AstraZeneca offer the **Enhertu4U** support program to provide information and assistance to patients who have been prescribed Enhertu. ◆

Daiichi-Sankyo and AstraZeneca's Oncology Drug

Drug	Indications	Patient support programs	Contact information
Enhertu (fam-trastuzumab deruxtecan-nxki) for injection	Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy; treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy; treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen; treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options	Enhertu4U	www.enhertu4u.com/hcp.html 833-364-3788
		Patient Savings Program Patient Assistance Program	www.enhertu4u.com/hcp/affordability.html 833-364-3788

Deciphera Pharmaceuticals AccessPoint

833-432-2237
www.romvimzahcp.com

Deciphera Pharmaceuticals offers patient support services through its **AccessPoint program** for patients who are prescribed Romvimza. ◆

Deciphera Pharmaceuticals Drug

Drug	Indication	Patient support programs	Contact information
Romvimza (vimseltinib)	Treatment of adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity	Copay Assistance Program Rapid Start Bridge Support Patient Assistance Program	www.romvimzahcp.com/resources 833-432-2237

Eisai Patient Support

866-613-4724
www.eisaipatientsupport.com

Eisai offers drug-specific reimbursement assistance to patients taking Halaven or Lenvima. ◆

Eisai Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Halaven (eribulin mesylate)	Treatment of metastatic breast cancer previously treated with at least 2 chemotherapeutic regimens; prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting; treatment of unresectable or metastatic liposarcoma previously treated with an anthracycline-containing regimen	Eisai Assistance Program Halaven $0 Co-Pay Program Halaven Patient Assistance Program	www.eisaipatientsupport.com/hcp/halaven/patient-support 866-613-4724
Lenvima (lenvatinib)	Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; in combination with pembrolizumab as first-line treatment of adult patients with advanced renal cell carcinoma (RCC); in combination with everolimus in advanced RCC following 1 prior anti-angiogenic therapy; as first-line treatment of unresectable hepatocellular carcinoma; in combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation	Lenvima Co-Pay Program	https://sservices.trialcard.com/Coupon/lenvatinib?p=Eisai 855-347-2448
		Lenvima Patient Assistance Program	www.eisaireimbursement.com/hcp/lenvima/patient-support 866-613-4724
		Lenvima Dose Exchange Program	www.eisaipatientsupport.com/-/media/Files/PatientSupport/LENV-US6039-Lenvima-Dose-Exchange-Enrollment-Form.pdf?hash=66374578-9626-4ddf-9cbe-9bb5fa73458d

EMD Serono CoverOne Support Services

844-826-8371
www.coverone.com

EMD Serono and Pfizer provide the **CoverOne** support services, a set of patient assistance programs that offer reimbursement services, copay assistance, and billing and coding resources for patients who are prescribed **Bavencio** (avelumab) or **Tepmetko** (tepotinib). ◆

EMD Serono Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Bavencio (avelumab) injection	Treatment of metastatic Merkel cell carcinoma for patients aged ≥12 years; maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, or that progressed with or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; first-line treatment of advanced renal cell carcinoma, in combination with axitinib	CoverOne Patient Assistance Program	www.coverone.com/en/Patient_Assistance/bavencio.html
		CoverOne Co-Pay Assistance Program	www.coverone.com/en/Co-Pay_Assistance/bavencio.html
Tepmetko (tepotinib) tablets	Metastatic non–small cell lung cancer harboring *MET* exon 14 skipping alterations	CoverOne Co-Pay Assistance Program	www.coverone.com/en/Co-Pay_Assistance/tepmetko.html
		CoverOne Patient Assistance Program	www.coverone.com/en/Patient_Assistance/tepmetko.html
		CoverOne Bridge Program	www.coverone.com/en/bridge-program/tepmetko.html

Exelixis Access Services

844-900-3273
www.ease.us
www.cometriq.com/hcp/access

Exelixis Access Services (EASE) includes programs designed to support patients who are prescribed Exelixis oncology drugs Cabometyx or Cometriq. ◆

Exelixis Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Cabometyx (cabozantinib) tablets	Treatment of patients with advanced renal cell carcinoma (RCC); first-line treatment of patients with advanced RCC in combination with nivolumab; treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib; treatment of adult and pediatric patients aged ≥12 years with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor–targeted therapy and who are radioactive iodine-refractory or ineligible	30-Day Free Trial Program Co-Pay Program Dose Exchange Program	www.ease.us 844-900-3273
Cometriq (cabozantinib) capsules	Treatment of progressive, metastatic medullary thyroid cancer	Co-Pay Program Patient Assistance Program	www.cometriq.com/hcp/access 844-900-3273

G1 Therapeutics G1 to One Patient Support Program

833-418-6663
www.cosela.com/patient-support

G1 Therapeutics offers the **G1 to One** patient support program for patients who are prescribed Cosela. ◆

G1 Therapeutics Oncology Drug

Drug	Indication	Patient support program	Contact information
Cosela (trilaciclib) for injection	To decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide or topotecan-containing regimen for extensive-stage small cell lung cancer	G1 Commercial Copay Program	https://portal.trialcard.com/g1portal 877-821-2465

Genentech Oncology My Patient Solutions

877-436-3683
www.genentech-access.com/hcp.html

Genentech provides support to help facilitate access to Genentech Oncology medicines for eligible patients. A list of Genentech Oncology medicines, indications, and program information is provided in the **Table**. ◆

Genentech Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Actemra (tocilizumab) injection	Treatment of cytokine release syndrome induced by CAR T-cell therapy	Actemra Co-pay Program	www.racopay.com/hcp 855-722-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Alecensa (alectinib)	Treatment of patients with *ALK*-positive metastatic non–small cell lung cancer (NSCLC), as detected by an FDA-approved test; adjuvant treatment following tumor resection in patients with *ALK*-positive NSCLC, as detected by an FDA-approved test	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Avastin (bevacizumab)	First- or second-line treatment of metastatic colorectal cancer (CRC), in combination with 5-fluorouracil–based chemotherapy; second-line treatment of metastatic CRC, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin–based chemotherapy in patients whose disease progressed with a first-line regimen containing bevacizumab; first-line treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell lung cancer, in combination with carboplatin and paclitaxel; recurrent glioblastoma in adults; treatment of metastatic renal cell carcinoma, in combination with interferon-alfa; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan; treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; treatment of unresectable or metastatic hepatocellular carcinoma, in combination with atezolizumab in patients who have not received prior systemic therapy	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Columvi (glofitamab-gxbm) injection	Treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331

Genentech Oncology... *(Continued)*

Genentech Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Cotellic (cobimetinib)	Treatment of unresectable or metastatic melanoma with *BRAF* V600E or V600K mutation, in combination with vemurafenib; treatment of adults with histiocytic neoplasms as a single agent	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Erivedge (vismodegib)	Treatment of adults with metastatic basal cell carcinoma, or patients with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and radiation	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Gazyva (obinutuzumab)	First-line treatment of chronic lymphocytic leukemia, in combination with chlorambucil; in combination with bendamustine followed by obinutuzumab monotherapy, treatment of follicular lymphoma relapsed after, or refractory to, a rituximab-containing regimen; in combination with chemotherapy followed by obinutuzumab monotherapy, for the treatment of patients achieving at least a partial remission, for previously untreated stage II bulky, III, or IV follicular lymphoma	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Herceptin (trastuzumab)	Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients based on an FDA-approved companion diagnostic for trastuzumab	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Herceptin Hylecta (trastuzumab + hyaluronidase-oysk) injection	Treatment of HER2-overexpressing breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Itovebi (inavolisib)	In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, *PIK3CA*-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy	Genentech Oncology Co-pay Assistance Program	www.itovebi-hcp.com/financial-support/assistance-options.html#copaycard
		Genentech Patient Foundation	www.itovebi-hcp.com/financial-support/assistance-options.html
Kadcyla (ado-trastuzumab emtansine)	Treatment of metastatic HER2-positive breast cancer in patients who previously received trastuzumab and a taxane separately or in combination; adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease after neoadjuvant taxane and trastuzumab-based therapy	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331

Genentech Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Lunsumio (mosunetuzumab-axgb) injection	Treatment of adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Perjeta (pertuzumab)	In combination with trastuzumab and docetaxel, for the treatment of HER2-positive metastatic breast cancer in patients without prior anti-HER2 therapy or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer; adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)	Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer; adjuvant treatment, in combination with chemotherapy, of patients with HER2-positive early-stage breast cancer at high risk of recurrence; treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Polivy (polatuzumab vedotin-piiq) for injection	In combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma and who have an International Prognostic Index score of ≥2; in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after ≥2 therapies	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Rituxan (rituximab)	Treatment of relapsed or refractory, low-grade or follicular CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent; treatment of peviously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; treatment of nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; treatment of previously untreated diffuse large B-cell lymphoma (DLBCL), CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens; treatment of pediatric patients aged ≥6 months with previously untreated, advanced-stage, CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia in combination with chemotherapy; treatment of adults with chronic lymphocytic leukemia	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331

Genentech Oncology... *(Continued)*

Genentech Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Rituxan Hycela (rituximab and hyaluronidase human) injection	Treatment of relapsed or refractory follicular lymphoma (FL); first-line treatment of FL, in combination with chemotherapy, and as maintenance monotherapy in patients with complete or partial response to rituximab plus chemotherapy; as monotherapy treatment for nonprogressing FL after first-line chemotherapy; treatment of previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone or other anthracycline-based chemotherapy regimens; treatment of chronic lymphocitic leukemia in combination with fludarabine and cyclophosphamide	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Rozlytrek (entrectinib)	Treatment of adults with metastatic non–small cell lung cancer with *ROS1* mutation, as detected by an FDA-approved test; treatment of adult and pediatric patients ≥1 month of age with solid tumors that have with *NTRK* gene fusion, as detected by an FDA-approved test, without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Tecentriq (atezolizumab)	Monotherapy adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II or IIIA non–small cell lung cancer (NSCLC) and PD-L1 expression, as determined by an FDA-approved test; first-line treatment of adults with metastatic NSCLC and high PD-L1 expression, as determined by an FDA-approved test, and no *EGFR* or *ALK* mutations; first-line treatment, in combination with bevacizumab, paclitaxel, and carboplatin, or in combination with paclitaxel protein-bound and carboplatin, of adults with metastatic nonsquamous NSCLC and no *EGFR* or *ALK* mutations; treatment of adults with metastatic NSCLC whose disease progressed during or after platinum-containing chemotherapy, or in patients with *EGFR* or *ALK* mutations whose disease progressed while using FDA-approved therapy for NSCLC harboring these mutations; first-line treatment, in combination with carboplatin and etoposide, of adults with extensive-stage small cell lung cancer; treatment, in combination with bevacizumab, of patients with unresectable or metastatic hepatocellular carcinoma who have not received previous systemic therapy; treatment, in combination with cobimetinib and vemurafenib, of patients with unresectable or metastatic melanoma and *BRAF* V600 mutation; treatment of adult and pediatric patients aged ≥2 years with unresectable or metastatic alveolar soft part sarcoma	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331

Genentech Oncology... *(Continued)*

Genentech Oncology Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Venclexta (venetoclax)	Treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma; treatment, in combination with azacitidine, or decitabine, or low-dose cytarabine, of newly diagnosed acute myeloid leukemia in patients aged ≥75 years, or those who have comorbidities that preclude use of intensive induction chemotherapy	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Xeloda (capecitabine)	Adjuvant treatment of patients with stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen; perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy; treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen; treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated; treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy; treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen; treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen; adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen	Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331
Zelboraf (vemurafenib)	Treatment of unresectable or metastatic melanoma with *BRAF* V600E mutation, as detected by an FDA-approved test; treatment of Erdheim-Chester disease with *BRAF* V600 mutation	Genentech Oncology Co-pay Assistance Program	www.copayassistancenow.com 855-692-6729
		Genentech Patient Foundation	www.gene.com/patients/patient-foundation 888-941-3331

Genmab Patient Support Services

866-628-2271
www.mynavcare.com/financial-assistance

855-473-2873
www.tivdak.com/resources-and-support/

Genmab offers patient support services through its **MyNavCare** program to assist patients who receive Epkinly and through its **Pfizer Oncology Together** patient assistance program for patients who receive Tivdak. ◆

Genmab Patient Support Services

Drugs	Indications	Patient support programs	Contact information
Epkinly (epcoritamab-bysp)	Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic therapy; treatment of adult patients with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy	MyNavCare Co-pay Program Genmab Patient Assistance Program	www.mynavcare.com/financial-assistance 866-628-2271
Tivdak (tisotumab vedotin-tftv)	Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy	Commercial Out-of-Pocket Assistance Program Patient Assistance Program Oncology Access Advocates	www.tivdakhcp.com/support-and-resources/ 855-473-2873

Geron REACH4RYTELO Patient Support Program

844-479-8356
www.rytelohcp.com/

The Geron REACH4RYTELO Patient Support Program can help your eligible patients who have been prescribed Rytelo navigate access and affordability. ◆

Patient Support Program | RYTELOHCP

Drug	Indication	Patient support programs	Contact information
Rytelo (imetelstat)	Treatment of adult patients with low- to intermediate-1-risk myelodysplastic syndromes with transfusion-dependent anemia requiring ≥4 red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents	Copay Program	www.rytelohcp.com/copay-program/ 844-479-8356
		Patient Support Program	www.rytelohcp.com/patient-support-program/ 844-479-8356

Gilead Sciences Support Services

844-876-3358
www.trodelvyhcp.com/support/access

844-622-2377
www.zydelig.com/resources-financial-support

Gilead Sciences offers the **Trodelvy Access Support** and the **Zydelig AccessConnect** programs for patients who are prescribed Trodelvy or Zydelig. ◆

Gilead Sciences Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Trodelvy (sacituzumab govitecan-hziy)	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received ≥2 prior systemic therapies, ≥1 of which was for metastatic disease; treatment of unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer in patients who have received endocrine-based therapy and ≥2 additional systemic therapies in the metastatic setting; treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor	Gilead Oncology Co-pay Program Gilead Patient Assistance Program	www.gileadoncologysupport.com/hcp#financial-support 844-876-3358
Zydelig (idelalisib)	Treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients in whom rituximab alone would be considered appropriate therapy due to other comorbidities	Financial information	www.zydelig.com/resources-financial-support 844-622-2377

Together with GSK Oncology Patient Support Services

844-447-5662
www.togetherwithgskoncology.com/hcp-resources

GSK offers the **Together with GSK Oncology** program for patients who are prescribed certain GSK oncology drugs. ◆

GSK Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Blenrep (belantamab mafodotin-blmf)	In combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received ≥2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent	Copay Assistance Program Patient Assistance Program	www.togetherwithgsk.com/blenrep/patient/cost-support/ 844-447-5665
Jemperli (dostarlimab-gxly) injection	In combination with carboplatin and paclitaxel followed by dostarlimab as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high; in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer; as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, who have progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation; as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following prior treatment and who have no satisfactory alternative treatment options	Copay Assistance Program Patient Assistance Program	www.togetherwithgskoncology.com/hcp-resources/jemperli/ 844-447-5662
Ojjaara (momelotinib) tablets	Treatment of intermediate- or high-risk myelofibrosis (MF), including primary or secondary MF, in adults with anemia	Copay Assistance Program Patient Assistance Program	www.togetherwithgskoncology.com/hcp-resources/ojjaara/ 844-447-5662
Zejula (niraparib)	Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of adult patients with deleterious or suspected deleterious germline *BRCA*-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, based on an FDA-approved companion diagnostic for niraparib	Copay Assistance Program Quick Start Program Bridge Program Patient Assistance Program	www.togetherwithgskoncology.com/hcp-resources/zejula/ 844-447-5662

Helsinn Cares Patient Support Services

844-357-4668
https://helsinnreimbursement.com

Helsinn Therapeutics offers the **Helsinn Cares** program that supports access, reimbursement, and assistance for patients who are prescribed a Helsinn Therapeutics oncology medication. ◆

Helsinn Oncology Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Akynzeo (netupitant and palonosetron) capsules	In combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeated use of chemotherapy, including emetogenic agents	Patient Assistance Program	www.helsinnreimbursement.com/patient-savings-programs 844-357-4668
		Akynzeo Capsule Savings Card	www.AKYNZEOsavingsprogram.com 844-357-4668
Akynzeo (fosnetupitant and palonosetron) injection	In combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy	Patient Assistance Program	www.helsinnreimbursement.com/patient-savings-programs 844-357-4668
Valchlor (mechlorethamine) gel	Topical treatment of stage IA/IB mycosis fungoides–type cutaneous T-cell lymphoma after skin-directed therapy	Valchlor Support Valchlor copay program	www.valchlorhcp.com/valchlor-support-patient-program 855-482-5245

Immunocore's KIMMTRAK CONNECT

844-775-2273
www.KIMMTRAKconnect.com

Immunocore offers the **KIMMTRAK CONNECT** program to deliver customized support for patients who have been prescribed Kimmtrak. ◆

Immunocore Oncology Drug

Drug	Indication	Patient support program	Contact information
Kimmtrak (tebentafusp-tebn) injection	Treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	Financial Assistance Program	www.kimmtrakconnect.com/financial-assistance/ 844-775-2273

ImmunoGen's Elahere Support Services

833-352-4373
www.elahere.com/resources/elahere-support-services#ESS

ImmunoGen offers **Elahere Support Services** to support patients who have been prescribed Elahere. ◆

ImmunoGen Oncology Drug			
Drug	**Indication**	**Patient support program**	**Contact information**
Elahere (mirvetuximab soravtansine-gynx)	Treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens; select patients for therapy based on an FDA-approved test	Co-pay Assistance Program Patient Assistance Program	www.elaherehcp.com/support 833-352-4373

IncyteCARES: Connecting to Access, Reimbursement, Education, and Support

855-452-5234
www.hcp.incytecares.com

Incyte offers **IncyteCARES (Connecting to Access, Reimbursement, Education, and Support)** to support patients who have been prescribed Jakafi, Monjuvi, Pemazyre, or Zynyz. ◆

Incyte Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Jakafi (ruxolitinib) tablets	Treatment of polycythemia vera in adults who have had an inadequate response to, or are intolerant of, hydroxyurea; treatment of intermediate- or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF in adults; treatment of steroid-refractory acute graft-versus-host disease in patients aged ≥12 years; treatment of chronic graft-versus-host disease after failure of 1 or 2 lines of systemic therapy in adult and pediatric patients aged ≥12 years	IncyteCARES for Jakafi Savings Program IncyteCARES for Jakafi Patient Assistance Program IncyteCARES for Jakafi Temporary Access Program	www.hcp.incytecares.com/oncology-hematology/jakafi/prescription-financial-assistance 855-452-5234
Monjuvi (tafasitamab-cxix) injection	In combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are ineligible for autologous stem cell transplant; in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma	IncyteCARES for Monjuvi Savings Program IncyteCARES for Monjuvi Patient Assistance Program	www.hcp.incytecares.com/oncology-hematology/monjuvi 855-452-5234
Pemazyre (pemigatinib) tablets	Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with *FGFR2* fusion or other rearrangement, as detected by an FDA-approved test; treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with *FGFR1* rearrangement	IncyteCARES for Pemazyre Savings Program IncyteCARES for Pemazyre Patient Assistance Program IncyteCARES for Pemazyre Temporary Access Program	www.hcp.incytecares.com/oncology-hematology/pemazyre 855-452-5234
Zynyz (retifanlimab-dlwr)	Treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma; first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) in combination with carboplatin and paclitaxel, and treatment of adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy as a single agent	IncyteCARES for Zynyz Savings Program IncyteCARES for Zynyz Patient Assistance Program	www.hcp.incytecares.com/oncology-hematology/zynyz 855-452-5234

IovanceCares Patient Support

833-400-4682
www.amtagvi.com/hcp/

Iovance provides patient support to patients receiving Amtagvi. ◆

Iovance Oncology Drug

Drug	Indications	Patient support program	Contact information
Amtagvi (lifileucel)	The treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if *BRAF* V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor	Patient Support	www.amtagvi.com/hcp/support-and-resources/resources/#iovance-cares 833-400-4682

IPSEN CARES: Coverage, Access, Reimbursement & Education Support

866-435-5677
www.ipsencares.com

Ipsen Biopharmaceuticals provides several patient support services through its **IPSEN CARES** (**Coverage, Access, Reimbursement & Education Support**) program to patients who are prescribed **Onivyde**, **Somatuline Depot**, **or Tazverik**. ◆

Ipsen Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Onivyde (irinotecan liposome) injection	Treatment of metastatic adenocarcinoma of the pancreas that progressed after gemcitabine-based therapy, in combination with fluorouracil and leucovorin; first-line treatment of metastatic pancreatic adenocarcinoma, with oxaliplatin, fluorouracil, and leucovorin	Onivyde Copay Assistance Program Onivyde Patient Assistance Program	www.ipsencares.com/onivyde-patient-support 866-435-5677
Somatuline Depot (lanreotide) injection	Treatment of carcinoid syndrome; unresectable, well-differentiated or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors	Somatuline Depot Copay Assistance Program Somatuline Depot Patient Assistance Program	www.ipsencares.com/somatuline-depot-patient-support 866-435-5677
Tazverik (tazemetostat) tablets	Treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma who are not eligible for complete resection; treatment of adults with relapsed or refractory follicular lymphoma (FL) and *EZH2* mutation, as detected by an FDA-approved test, who have received ≥2 prior systemic therapies; treatment of adults with relapsed or refractory FL who have no satisfactory alternative treatment options	Tazverik Copay Assistance Program Tazverik Patient Assistance Program Tazverik Quick Start Program Tazverik Bridge Supply Program	www.ipsencares.com/tazverik-patient-support www.tazverik.com/epithelioid-sarcoma/support 866-435-5677

JazzCares Patient Support Services

833-533-5299
https://jazzcares.com/hcp

Jazz Pharmaceuticals, through its **JazzCares Patient programs**, offers access and reimbursement support and financial assistance options to patients who are prescribed its hematology/oncology drugs. ◆

Jazz Pharmaceuticals Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Defitelio (defibrotide sodium)	Treatment of adult and pediatric patients with hepatic veno-occlusive disease associated with renal or pulmonary dysfunction after hematopoietic stem cell transplantation	JazzCares	www.defitelio.com/defitelio-resources/index 833-533-5299
Modeyso (dordaviprone)	Treatment of adult and pediatric patients aged ≥1 year with diffuse midline glioma harboring an *H3 K27M* mutation with progressive disease following prior therapy	Copay Assistance Patient Assistance Program Temporary Supply	www.modeysohcp.com/resources#access-and-patient-support 844-302-2737
Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn)	As a component of a multiagent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients aged ≥1 month who have developed hypersensitivity to *Escherichia coli*–derived asparaginase	Travel and Lodging Assistance Program Savings Card Patient Assistance Program	www.jazzcares.com/hcp/rylaze 833-533-5299
Vyxeos (daunorubicin and cytarabine) liposome	Adults and pediatric patients aged ≥1 year with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes	Savings Card Patient Assistant Program	www.jazzcares.com/hcp/vyxeos 833-533-5299
Zepzelca (lurbinectedin)	Treatment of adults with metastatic small cell lung cancer with disease progression during or after platinum-based chemotherapy; in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide	Savings Card Patient Assistant Program	www.jazzcares.com/hcp/zepzelca 833-533-5299

Johnson & Johnson withMe Program

833-565-9631
www.jnjwithme.com/hcp/

The **Johnson & Johnson withMe** program offers financial assistance to patients who are prescribed a J&J oncology medication. ◆

Janssen Biotech Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Balversa (erdafitinib) tablets	Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible *FGFR3* or *FGFR2* genetic alteration, as determined by an FDA-approved test, that has progressed during or after ≥1 line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy	Johnson & Johnson withMe Savings Program	www.balversahcp.com/support-and-resources 844-494-8463
Darzalex (daratumumab)	Treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma after ≥1 previous therapies; in combination with bortezomib, melphalan, and prednisone in newly diagnosed patients ineligible for ASCT; in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received ≥1 prior therapies; in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received 1-3 lines of therapy; in combination with pomalidomide and dexamethasone after ≥2 previous therapies, including lenalidomide and a proteasome inhibitor (PI); as monotherapy in patients who have received ≥3 prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/darzalex/affordability/ 833-565-9631
		Darzalex withMe	www.account1.jnjwithme.com/oncology 833-565-9631

Johnson & Johnson withMe... *(Continued)*

Janssen Biotech Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Darzalex Faspro (daratumumab and hyaluronidase-fihj)	Treatment of adults with multiple myeloma (MM): in combination with bortezomib, melphalan, and prednisone, in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT); in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory MM who have received ≥1 prior therapies; in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received ≥1 prior therapies; in combination with pomalidomide and dexamethasone in patients who have received ≥1 prior therapies including lenalidomide and a proteasome inhibitor (PI); as monotherapy after ≥3 previous lines of therapy, including a PI and an immunomodulatory agent, or in patients who are double-refractory to a PI and an immunomodulatory agent; in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/darzalex-faspro/affordability/ 833-565-9631
		Darzalex withMe	www.account1.jnjwithme.com/oncology 833-565-9631
Erleada (apalutamide)	Treatment of metastatic castration-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/erleada/affordability/ 833-565-9631
		Earleda withMe	www.account1.jnjwithme.com/oncology 833-565-9631
Rybrevant (amivantamab-vmjw)	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with *EGFR* exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy; treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/rybrevant/affordability/ 833-565-9631
		Rybrevant withMe	www.account1.jnjwithme.com/oncology 833-565-9631

Johnson & Johnson withMe... *(Continued)*

Janssen Biotech Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Talvey (talquetamab-tgvs)	Treatment of adults with relapsed/refractory multiple myeloma who received ≥4 previous lines of therapy, including proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/talvey/affordability/ 833-565-9631
		Talvey withMe	www.account1.jnjwithme.com/oncology 833-565-9631
Tecvayli (teclistamab-cqyv)	Treatment of adult patients with relapsed or refractory multiple myeloma who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody	Johnson & Johnson withMe Savings Program	https://www.jnjwithme.com/hcp/tecvayli/affordability/ 833-565-9631
		Tecvayli withMe	www.account1.jnjwithme.com/tecvayli-withme/account/sign-up 833-565-9631
Yondelis (trabectedin)	Treament of unresectable or metastatic liposarcoma or leiomyosarcoma in patients who received a prior anthracycline-containing regimen	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/yondelis/affordability/ 877-227-3728
Zytiga (abiraterone acetate) tablets	Treament of metastatic castration-resistant prostate cancer, in combination with prednisone; metastatic high-risk, castration-sensitive prostate cancer, in combination with prednisone	Johnson & Johnson withMe Savings Program	www.jnjwithme.com/hcp/zytiga/affordability/ 877-227-3728

Karyopharm KaryForward Patient Support Services

877-527-9493
www.karyforward.com/hcp

Karyopharm Therapeutics offers comprehensive patient support services through its **KaryForward** program to facilitate access to Karyopharm's oncology medication, Xpovio, including reimbursement support and patient financial assistance. ◆

Karyopharm Therapeutics Oncology Drug

Drug	Indications	Patient support programs	Contact information
Xpovio (selinexor)	Treatment of adults with multiple myeloma (MM), in combintion with bortezomib and dexamethasone, who have received ≥1 prior therapy; treatment, in combination with dexamethasone, in adults with relapsed or refractory MM who have received ≥4 prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and an anti-CD38 monoclonal antibody; treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after ≥2 lines of systemic therapy	Xpovio Copay Program Patient Assistance Program QuickStart Program Bridge Program Dose Exchange Program	www.karyforward.com/hcp 877-527-9493

Kite Pharma: Kite Konnect

844-454-5483
www.kitekonnect.com

Kite Pharma offers **Kite Konnect**, a program committed to helping patients and healthcare teams throughout treatment with Tecartus or Yescarta. ◆

Kite Pharma Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Tecartus (brexucabtagene autoleucel)	Treatment of adult patients with relapsed or refractory mantle-cell lymphoma; treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia	Kite Konnect	www.kitekonnect.com 844-454-5483
Yescarta (axicabtagene ciloleucel)	Treatment of adult patients with B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy; treatment of adult patients with relapsed or refractory large B-cell lymphoma after ≥2 lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma; treatment of adult patients with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy	Kite Konnect	www.kitekonnect.com 844-454-5483

Lilly Oncology Support Center

800-545-5979
www.oncologysupport.lilly.com/hcp

Eli Lilly and Company, through Lilly Oncology, offers financial assistance to qualified patients who are prescribed oncology medications. ◆

Lilly Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Alimta (pemetrexed) for injection	Initial treatment in combination with pembrolizumab and platinum chemotherapy for nonsquamous metastatic non–small cell lung cancer (NSCLC) with no *EGFR* or *ALK* genomic tumor aberrations; initial treatment in combination with cisplatin for locally advanced or metastatic nonsquamous NSCLC; single agent in recurrent metastatic nonsquamous NSCLC after prior chemotherapy; single agent as maintenance therapy in patients with locally advanced or metastatic nonsquamous NSCLC whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy; in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery	Lilly Cares Foundation	www.lillycares.com 800-545-6962
Cyramza (ramucirumab)	As a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy; in combination with erlotinib, for first-line treatment of metastatic non–small cell lung cancer (NSCLC) with *EGFR* exon 19 deletions or exon 21 (L858R) mutations; in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy. Patients with *EGFR* or *ALK* genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Cyramza. In combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine; as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib	Savings Card Program	www.oncologysupport.lilly.com/cyramza-financial-support 800-545-5979
		Lilly Cares Foundation	www.lillycares.com 800-545-6962
Erbitux (cetuximab)	Treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), in combination with radiation; treatment of patients with recurrent locoregional disease or metastatic SCCHN, in combination with platinum-based therapy; treatment of recurrent or metastatic SCCHN after progressing on platinum-based therapy; treatment of metastatic colorectal cancer that is *EGFR*-expressing, *KRAS* wild-type, as determined by an FDA-approved test: as first-line treatment, in combination with FOLFIRI or in combination with irinotecan, in disease refractory to irinotecan-based chemotherapy; as a single agent in patients progressing after oxaliplatin- and irinotecan-based chemotherapy or intolerant to irinotecan	Savings Card Program	www.oncologysupport.lilly.com/erbitux-financial-support 800-545-5979
		Lilly Cares Foundation	www.lillycares.com 800-545-6962

Lilly Oncology Support Center... *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Inluriyo (imlunestrant)	Treatment of adults with estrogen receptor–positive, HER2-negative, *ESR1*-mutated advanced or metastatic breast cancer with disease progression following ≥1 line of endocrine therapy	Inluriyo Savings Card	www.inluriyo.lilly.com/savings-support 800-545-5979
Jaypirca (pirtobrutinib) tablets	Treatment of adult patients with relapsed or refractory mantle cell lymphoma after ≥2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received ≥2 prior lines of therapy, including a BTK inhibitor and a B-cell leukemia/lymphoma-2 inhibitor	Jaypirca Savings Card Jaypirca Interim Access Program MyRightDose Program	www.jaypirca.com/hcp/savings-support 800-545-5979
		Lilly Cares Foundation	www.lillycares.com 800-545-6962
Retevmo (selpercatinib) capsules	Treatment of adults with locally advanced or metastatic *RET* fusion–positive non–small cell lung cancer, as detected by an FDA-approved test; treatment of patients aged ≥2 years with advanced or metastatic medullary thyroid cancer and *RET* mutation, as detected by an FDA-approved test, who require systemic therapy; treatment of patients aged ≥2 years with advanced or metastatic *RET* fusion–positive thyroid cancer, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine–refractory (if radioactive iodine is appropriate); treatment of patients aged ≥2 years with locally advanced or metastatic solid tumors with a *RET* gene fusion who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options	Retevmo Savings Card MyRightDose Program	www.retevmo.lilly.com/hcp/savings-support#savingscard 800-545-5979
		Lilly Cares Foundation	www.lillycares.com 800-545-6962
Verzenio (abemaciclib) tablets	In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence; as initial endocrine-based therapy, in combination with an aromatase inhibitor, for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, for disease that progressed after endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, as monotherapy, for disease that progressed after endocrine therapy and previous chemotherapy in the metastatic setting	Verzenio Savings Card MyRightDose Program	www.verzenio.lilly.com/hcp/savings-support 800-545-5979
		Lilly Cares Foundation	www.lillycares.com 800-545-6962

MacroGenics' Margenza Access Support

844-633-6469
www.margenzasupport.com

MacroGenics offers the **Margenza Access Support** program to assist patients and their healthcare providers with access to Margenza. ◆

MacroGenics Oncology Drug			
Drug	**Indication**	**Patient support programs**	**Contact information**
Margenza (margetuximab-cmkb)	In combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received ≥2 prior anti-HER2 regimens, at least 1 of which was for metastatic disease	Copay Assistance Program Patient Assistance Program	www.margenzasupport.com/hcp/financial-support 844-633-6469

Medexus Pharma, Inc. CORE Connections

844-723-2739
www.grafapex.com/patient-support

Medexus Pharma offers patient support services through its **CORE Connections program** for patients who are prescribed Grafapex. ◆

Medexus Pharma Drug			
Drug	**Indications**	**Patient support program**	**Contact information**
Grafapex (treosulfan)	Treatment, in combination with fludarabine as a preparative regimen, for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients aged ≥1 year with acute myeloid leukemia; treatment, in combination with fludarabine as a preparative regimen, for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients aged ≥1 year with myelodysplastic syndrome	Copay Assistance Program	https://www.grafapex.com/patient-support 844-723-2739

Merck Helps/Merck Access Program

800-727-5400
www.merckhelps.com/programs.aspx

855-257-3932
www.merckaccessprogram.com/

Merck Helps offers a full suite of support services, including the **Merck Patient Assistance Program**, the **Merck Access Program**, and the **Merck Co-pay Assistance Program**. ◆

Merck Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Emend capsules (aprepitant)	Prevention of nausea and vomiting caused by chemotherapy in patients ≥12 years of age	Merck Patient Assistance Program	www.merckhelps.com/EMEND%20CAPSULES 800-727-5400
Emend for oral suspension (aprepitant)	Prevention of nausea and vomiting caused by chemotherapy in patients ≥6 months of age	Merck Patient Assistance Program	www.merckhelps.com/EMEND%2ORAL%20SUSPENSION 800-727-5400
Emend for injection (fosaprepitant)	Prevention and treatment of nausea and vomiting caused by chemotherapy in patients ≥6 months of age	Merck Patient Assistance Program	www.merckhelps.com/EMEND%20FOR%20INJECTION 800-727-5400
		Hospital Product Replacement Program	www.merckhelps.com/Programs.aspx?tab=MHL 888-727-9535
Keytruda (pembrolizumab)	Melanoma • for the treatment of patients with unresectable or metastatic melanoma • for the adjuvant treatment of adult and pediatric (≥12 years) patients with stage IIB, IIC, or III melanoma following complete resection Non-Small Cell Lung Cancer (NSCLC) • in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no *EGFR* or *ALK* genomic tumor aberrations • in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC	Merck Access Program	www.merckaccessprogram-keytruda.com/hcp/ 855-257-3932
		Merck Co-pay Assistance Program	www.merckaccessprogram-keytruda.com/hcp/affordability.html 855-257-3932
		Merck Patient Assistance Program	www.merckhelps.com/KEYTRUDA 855-257-3932

Merck Helps/Merck Access... *(Continued)*

Merck Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Keytruda (pembrolizumab) *(cont)*	• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no *EGFR* or *ALK* genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic • as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with *EGFR* or *ALK* genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda • for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery • as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC Head and Neck Squamous Cell Cancer (HNSCC) • in combination with platinum and fluorouracil for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC • as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (combined positive score [CPS] ≥1) as determined by an FDA-approved test • for the treatment of adults with resectable locally advanced HNSCC whose tumors express PD-L1 [CPS ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent • as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy • for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) • for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after ≥2 lines of therapy • for the treatment of adults with resectable locally advanced HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test • as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent		

Merck Helps/Merck Access... *(Continued)*

Merck Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Keytruda (pembrolizumab) *(cont)*	Primary Mediastinal Large B-Cell Lymphoma (PMBCL) • for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after ≥2 prior lines of therapy Urothelial Carcinoma • in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy • as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy • as a single agent for the treatment of patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Cancer • for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options MSI-H or dMMR Colorectal Cancer (CRC) • for the treatment of patients with unresectable or metastatic MSI-H or dMMR CRC as determined by an FDA-approved test Gastric Cancer • in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test • in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma Esophageal Cancer • for the treatment of patients with locally advanced or metastatic esophageal or GEJ (tumors with epicenter 1-5 cm above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either in combination with platinum- and fluoropyrimidine-based chemotherapy, or as a single agent after ≥1 prior line of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test		

Merck Helps/Merck Access... *(Continued)*

Merck Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Keytruda (pembrolizumab) *(cont)*	Cervical Cancer • in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test • as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test Treatment of patients with FIGO 2014 stage III-IVA cervical cancer with chemoradiotherapy Hepatocellular Carcinoma (HCC) • for the treatment of patients with HCC who have been previously treated with sorafenib Biliary Tract Cancer (BTC) • in combination with gemcitabine/cisplatin, for the treatment of patients with locally advanced unresectable or metastatic BTC Merkel Cell Carcinoma (MCC) • for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC Renal Cell Carcinoma (RCC) • in combination with axitinib, for the first-line treatment of adult patients with advanced RCC • in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC • for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions Endometrial Carcinoma • in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient as determined by an FDA-approved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation • as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation • treatment of adult patients with primary advanced or recurrent endometrial carcinoma, with carboplatin and paclitaxel followed by single-agent pembrolizumab Tumor Mutational Burden-High (TMB-H) Cancer • for the treatment of adult and pediatric patients with unresectable or metastatic TMB-H (≥10 mutations/megabase) solid tumors, as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment options Cutaneous Squamous Cell Carcinoma (cSCC) • for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation		

Merck Helps/Merck Access... *(Continued)*

Merck Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Keytruda (pembrolizumab) *(cont)*	Triple-Negative Breast Cancer (TNBC) • for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery • in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test Adult Classical Hodgkin Lymphoma • as a single agent for the treatment of patients with recurrent or metastatic cHL • for the treatment of adult patients with relapsed or refractory cHL • for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after ≥2 lines of therapy Malignant Pleural Mesothelioma (MPM) • First-line treatment of patients with unresectable advanced or metastatic MPM, with pemetrexed and platinum chemotherapy		
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph)	See Keytruda indications above for Keytruda Qlex uses	Merck Patient Assistance Program	www.keytruda.com/qlex/ 855-257-3932
Noxafil (posaconazole) injection, delayed-release tablets	Treatment of invasive aspergillosis in adults and pediatric patients ≥13 years of age; prevention of invasive *Aspergillus* and *Candida* infections associated with hematologic cancer or stem cell transplantation in patients ≥2 years of age	Merck Patient Assistance Program	www.merckhelps.com/Programs.aspx?tab=MHL 800-727-5400
Noxafil (posaconazole) oral suspension	Prevention of invasive *Aspergillus* and *Candida* infections associated with hematologic cancer or stem cell transplantation in patients ≥13 years of age	Merck Patient Assistance Program	www.merckhelps.com/Programs.aspx?tab=MHL 800-727-5400
Welireg (belzutifan) tablets	Treatment of adult patients with advanced renal cell carcinoma following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor; treatment of adult and pediatric patients aged ≥12 years with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma	Merck Co-pay Coupon	www.merckaccessprogram-welireg.com/hcp/copay-assistance-options-for-eligible-patients/
		Merck Patient Assistance Program	www.merckaccessprogram-welireg.com/hcp/merck-patient-assistance-program/

Novartis Oncology's Patient Support

888-669-6682
www.novartis.com/us-en/patients-and-caregivers/patient-assistance

Novartis Oncology provides a full range of patient support services through **Novartis Support.** ◆

Novartis Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Afinitor (everolimus) tablets/ Afinitor Disperz (everolimus tablets for oral suspension)	Treatment of postmenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole; adults with progressive neuroendocrine tumors of pancreatic origin and adults with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic disease; adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib; adults with renal angiomyolipoma and tuberous sclerosis complex not requiring immediate surgery	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Arzerra (ofatumumab)	Treatment of chronic lymphocytic leukemia (CLL): • in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate • in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL • for extended treatment of patients who are in complete or partial response after ≥2 lines of therapy for recurrent or progressive CLL • for the treatment of patients with CLL refractory to fludarabine and alemtuzumab	Arzerra Oncology Access Program	800-282-7630
Exjade (deferasirox)	Treatment of chronic iron overload due to blood transfusions in patients aged ≥2 years Treatment of chronic iron overload in patients aged ≥10 years with non-transfusion-dependent thalassemia syndromes, and with a liver iron (Fe) concentration of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 µg/L	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756

Novartis Oncology's Patient Support... *(Continued)*

Novartis Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Gleevec (imatinib mesylate)	Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase; Ph+ CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy; relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL); newly diagnosed Ph+ ALL in combination with chemotherapy; myelodysplastic/ myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements; aggressive systemic mastocytosis without the *D816V c-Kit* mutation or with *c-Kit* mutational status unknown; hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) in patients who have the *FIP1L1-PDGFRα* fusion kinase and for patients with HES and/or CEL who are *FIP1L1-PDGFRα* fusion kinase negative or unknown; unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans; *Kit (CD117)*-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST); adjuvant treatment of adult patients following resection of *Kit (CD117)*-positive GIST	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
Jadenu (deferasirox) tablets	Treatment of chronic iron overload in patients aged ≥10 years with non-transfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 μg/L	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Kisqali (ribociclib) tablets	Treatment of adults with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor; postmenopausal adults with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression on endocrine therapy, in combination with fulvestrant	Novartis Patient Support	www.kisqali-hcp.com/early-breast-cancer/novartis-patient-support www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support
		Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254

Novartis Oncology's Patient Support... *(Continued)*

Novartis Oncology/Supportive Care Drugs *(Continued)*			
Drugs	**Indications**	**Patient support programs**	**Contact information**
Kymriah (tisagenlecleucel)	Treatment of patients up to 25 years with relapsed or refractory B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse; adults with relapsed or refractory large B-cell lymphoma after ≥2 lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (FL); adults with relapsed or refractory FL after ≥2 lines of systemic therapy	Kymriah Cares	https://us.kymriah.com/acute-lymphoblastic-leukemia-children/patient-support/support-resources-for-kymriah 844-459-6742
Mekinist (trametinib)	Single agent in BRAF-inhibitor treatment-naive patients, or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with *BRAF* V600E or V600K mutations, as detected by an FDA-approved test; in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with *BRAF* V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection; in combination with dabrafenib, for the treatment of patients with metastatic non–small cell lung cancer with *BRAF* V600E mutation, as detected by an FDA-approved test; in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with *BRAF* V600E mutation and no satisfactory locoregional treatment options; in combination with dabrafenib for the treatment of patients ≥1 year of age with unresectable or metastatic solid tumors with *BRAF* V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options; treatment of pediatric patients ≥1 year of age with low-grade glioma with a *BRAF* V600E mutation who require systemic therapy	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Piqray (alpelisib)	Treatment, in combination with fulvestrant, of postmenopausal women, and men, with hormone receptor–positive, HER2-negative, advanced or metastatic breast cancer and *PIK3CA* mutation, as detected by an FDA-approved test, that is progressing during or after an endocrine-based regimen	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254

Novartis Oncology's Patient Support... *(Continued)*

Novartis Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)	Treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibitor therapy and are considered appropriate to delay taxane-based chemotherapy or have received prior taxane-based chemotherapy	Co-Pay Plus Novartis Patient Assistance Foundation, Inc.	www.pluvicto-hcp.com/psma-positive-mcrpc/novartis-patient-support 844-638-7222
Promacta (eltrombopag)	Treatment of: • thrombocytopenia in adult and pediatric patients ≥1 year with persistent or chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; • thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy; • in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients ≥2 years with severe aplastic anemia; • patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Rydapt (midostaurin) capsules	Treatment of newly diagnosed adults with acute myeloid leukemia with *FLT3* mutation, in combination with cytarabine and daunorubicin induction and high-dose cytarabine consolidation; aggressive systemic mastocytosis, systemic mastocytosis with hematologic neoplasm, or mast-cell leukemia in adults	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Sandostatin LAR Depot (octreotide acetate for injectable suspension)	Treatment of severe diarrhea or flushing episodes in metastatic carcinoid; acromegaly; profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumors	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Scemblix (asciminib)	Treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with ≥2 tyrosine kinase inhibitors; treatment of adult patients with Ph+ CML in CP with the *T315I* mutation	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
		30-Day Voucher	https://svc.opushealth.com/ScemblixVoucherPOD
Tabrecta (capmatinib)	Treatment of metastatic non–small cell lung cancer in adult patients whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254

Novartis Oncology's Patient Support... *(Continued)*

Novartis Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Tafinlar (dabrafenib)	Single agent in BRAF-inhibitor treatment-naive patients, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with *BRAF* V600E or V600K mutations, as detected by an FDA-approved test; in combination with trametinib, for the adjuvant treatment of patients with melanoma with *BRAF* V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection; in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer with *BRAF* V600E mutation, as detected by an FDA-approved test; in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with *BRAF* V600E mutation and with no satisfactory locoregional treatment options; in combination with trametinib for the treatment of patients ≥1 year of age with unresectable or metastatic solid tumors with *BRAF* V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options; the treatment of pediatric patients ≥1 year of age with low-grade glioma with a *BRAF* V600E mutation who require systemic therapy	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Tasigna (nilotinib)	Treatment of adult and pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); treatment of adult patients with CP and accelerated phase Ph+ CML resistant or intolerant to prior therapy that included imatinib; treatment of pediatric patients ≥1 year of age with CP and accelerated phase Ph+ CML with resistance or intolerance to prior tyrosine kinase inhibitor therapy	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Tykerb (lapatinib)	In combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab; in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254

Novartis Oncology's Patient Support... *(Continued)*

Novartis Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Votrient (pazopanib)	Treatment of adults with advanced renal cell carcinoma; advanced soft-tissue sarcoma in patients who have received prior chemotherapy	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254
Zykadia (ceritinib)	Treatment of metastatic non-small cell lung cancer with *ALK* mutation, as detected by an FDA-approved test	Novartis Oncology Universal Co-pay Program	www.copay.novartisoncology.com 877-577-7756
		Novartis Patient Assistance Foundation	www.pap.novartis.com 800-277-2254

Nuvation Bio NuvationConnect

877-688-2661
www.ibtrozihcp.com/support-and-access/#patient-support-program

Nuvation Bio, through its **NuvationConnect program**, offers 5 financial assistance programs for patients receiving Ibtrozi. ◆

Nuvation Bio Drug

Drug	Indication	Patient support programs	Contact information
Ibtrozi (taletrectinib)	Treatment of adult patients with locally advanced or metastatic *ROS1*-positive non-small cell lung cancer	Copay Assistance Quick Start Program Bridge Program Free Trial Offer Patient Assistance Program	www.nuvationconnect.com/en/portal 877-688-2661

The Organon Access Program

844-326-2986
www.organonaccessprogram-ontruzant.com/hcp

Organon offers **The Organon Access Program** to assist patients who have been prescribed Ontruzant. ◆

Organon Oncology Drug

Drug	Indication	Patient support programs	Contact information
Ontruzant (trastuzumab-dttb)	The treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma	The Organon Co-pay Assistance Program	www.organonaccessprogram-ontruzant.com/hcp/the-organon-copay-assistance-program/ 844-326-2986
		The Organon Patient Assistance Program	www.organonaccessprogram-ontruzant.com/hcp/the-organon-patient-assistance-program/ 844-326-2986

Partner Therapeutics, Inc. PTx Assist

877-353-8546
www.bizengrihcp.com/#PATIENT-SUPPORT

Partner Therapeutics offers patient support services through its **PTx Assist** program for patients who are prescribed **Bizengri**. ◆

Partner Therapeutics Drug

Drug	Indications	Patient support programs	Contact information
Bizengri (zenocutuzumab-zbco)	Treatment of adults with advanced, unresectable or metastatic non–small cell lung cancer harboring an *NRG1* gene fusion with disease progression on or after prior systemic therapy; treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring an *NRG1* gene fusion with disease progression on or after prior systemic therapy	Patient Assistance Copay Assistance	www.bizengrihcp.com/#PATIENT-SUPPORT 877-353-8546

Pfizer Oncology Together

877-744-5675
www.pfizeroncologytogether.com/hcp

Pfizer offers **Pfizer Oncology Together**, a patient support program to help patients access their prescribed Pfizer Oncology medications, identify financial assistance options, and connect patients to a dedicated Care Champion. ◆

Pfizer Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Besponsa (inotuzumab ozogamicin)	Treatment of adult and pediatric patients aged ≥1 year with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll https://besponsa.pfizerpro.com/ 877-744-5675
		Pfizer Patient Assistance Program	www.pfizerpro.com/patient-assistance
Bosulif (bosutinib)	Treatment of adult and pediatric patients aged ≥1 year with chronic phase Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML), newly diagnosed or resistant or intolerant to prior therapy; adult patients with accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Braftovi (encorafenib)	Treatment, in combination with binimetinib, of patients with unresectable or metastatic melanoma and a *BRAF* V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with cetuximab, of adults with metastatic colorectal cancer and a *BRAF* V600E mutation, as detected by an FDA-approved test, after previous therapy; treatment, in combination with binimetinib, of adult patients with metastatic non–small cell lung cancer with a *BRAF* V600E mutation, as detected by an FDA-approved test	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Daurismo (glasdegib)	In combination with low-dose cytarabine, treatment of newly diagnosed acute myeloid leukemia in adults aged ≥75 years or patients whose comorbidities preclude intensive chemotherapy induction	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll https://daurismo.pfizerpro.com/support-your-patient/access-and-patient-support 877-744-5675
		Pfizer Patient Assistance Program	www.pfizeroncologytogether.com/hcp/patient-financial-assistance#insurance-types

Pfizer Oncology Together *(Continued)*

Pfizer Oncology/Supportive Care Drugs *(Continued)*			
Drugs	**Indications**	**Patient support programs**	**Contact information**
Elrexfio (elranatamab-bcmm)	Treatment of adults with relapsed/refractory multiple myeloma who received ≥4 lines of previous therapy, including proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Portal	www.pfizeroncologytogether.com/hcp/patient-copay-registration www.pfizercopay.com 800-555-4820
Ibrance (palbociclib)	Treatment of adult patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients with disease progression following endocrine therapy	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Oncology Together Co-Pay Savings Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Inlyta (axitinib)	In combination with avelumab, for the first-line treatment of advanced renal cell carcinoma (RCC); in combination with pembrolizumab, for the first-line treatment of advanced RCC; as a single agent, for the treatment of advanced RCC after failure of 1 prior systemic therapy	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Lorbrena (lorlatinib)	Treatment of metastatic non–small cell lung cancer with *ALK* mutation, as determined by an FDA-approved test	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Mektovi (binimetinib)	Treatment, in combination with encorafenib, of patients with unresectable or metastatic melanoma and a *BRAF* V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with encorafenib, of adult patients with metastatic non–small cell lung cancer with a *BRAF* V600E mutation, as detected by an FDA-approved test	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Mylotarg (gemtuzumab ozogamicin)	Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged ≥1 month; treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients aged ≥2 years	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675

Pfizer Oncology Together *(Continued)*

Pfizer Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Nivestym (filgrastim-aafi) injection	To decrease the incidence of infection (as manifested by febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever; reduce time to neutrophil recovery and duration of fever after chemotherapy in patients with acute myeloid leukemia; to reduce duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplant; for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to reduce incidence/duration of severe neutropenia sequelae in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Portal	www.pfizeroncologytogether.com/hcp/patient-copay-registration www.pfizercopay.com 800-555-4820
Nyvepria (pegfilgrastim-apgf)	To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Portal	www.pfizeroncologytogether.com/hcp/patient-copay-registration www.pfizercopay.com 800-555-4820

Pfizer Oncology Together *(Continued)*

Pfizer Oncology/Supportive Care Drugs *(Continued)*

Drugs	Indications	Patient support programs	Contact information
Ruxience (rituximab-pvvr)	Treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; nonprogressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone, or other anthracycline-based chemotherapy regimens; in combination with fludarabine and cyclophosphamide, for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Portal	www.pfizeroncologytogether.com/hcp/patient-copay-registration www.pfizercopay.com 800-555-4820
Sutent (sunitinib malate)	Treatment of adult patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; treatment of adult patients with advanced renal cell carcinoma (RCC); adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy; treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in adult patients with unresectable locally advanced or metastatic disease	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll https://sutent.pfizerpro.com/ 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Talzenna (talazoparib)	As a single-agent treatment of adult patients with deleterious or suspected deleterious germline *BRCA*-mutated, HER2-negative, locally advanced or metastatic breast cancer, based on an FDA-approved companion diagnostic; in combination with enzalutamide for the treatment of adult patients with *HRR*-mutated, metastatic castration-resistant prostate cancer	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Trazimera (trastuzumab-qyyp)	Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Portal	www.pfizeroncologytogether.com/hcp/patient-copay-registration www.pfizercopay.com 800-555-4820

Pfizer Oncology Together *(Continued)*

Pfizer Oncology/Supportive Care Drugs			
Drugs	**Indications**	**Patient support programs**	**Contact information**
Vizimpro (dacomitinib)	First-line treatment of metastatic non–small cell lung cancer with *EGFR* exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Xalkori (crizotinib)	Treatment of patients with metastatic non–small cell lung cancer whose tumors are *ALK*- or *ROS1*-positive, as detected by an FDA-approved test; pediatric patients aged ≥1 year and young adults with relapsed or refractory, systemic anaplastic large-cell lymphoma that is *ALK*-positive; adult and pediatric patients aged ≥1 year with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor that is *ALK*-positive	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Assistance Program	www.pfizeroncologytogether.com/hcp/patient-copay-registration
Zirabev (bevacizumab-bvzr)	First- or second-line treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy; second-line treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab regimen	Pfizer Oncology Together	www.pfizeroncologytogether.com/hcp/enroll 877-744-5675
		Pfizer Co-Pay Portal	www.pfizercopay.com

Pharmacyclics and Johnson & Johnson: Imbruvica By Your Side Patient Support Program

888-968-7743
www.imbruvicahcp.com/patient-support-program

Pharmacyclics and Johnson & Johnson offer the **Imbruvica By Your Side** patient support program to assist patients while taking Imbruvica. This program offers personalized support to help patients access and stay on track with Imbruvica. ◆

Pharmacyclics Oncology Drug

Drug	Indications	Patient support programs	Contact information
Imbruvica (ibrutinib)	Treatment of adults with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma (SLL), including CLL or SLL with 17p deletion; adults with Waldenström macroglobulinemia; and adults and pediatric patients age ≥1 year with chronic graft-versus-host disease, after failure of ≥1 line of systemic therapy	Imbruvica Copay Card	www.imbruvicahcp.com/imbruvica-by-your-side-copay-card 888-968-7743
		Dose Exchange Program	www.imbruvicahcp.com/dose-exchange-prescription-enrollment-form.pdf 888-968-7743

Puma Biotechnology Support Services

855-816-5421
https://nerlynxhcp.com/access-and-support

Puma Biotechnology offers **Puma Patient Lynx** to assist patients while taking Nerlynx. ◆

Puma Biotechnology Oncology Drug

Drug	Indications	Patient support programs	Contact information
Nerlynx (neratinib) tablets	Extended adjuvant treatment of adults with early-stage HER2-positive breast cancer, after adjuvant trastuzumab-based therapy; treatment, in combination with capecitabine, of advanced or metastatic HER2-positive breast cancer in adults, after ≥2 HER2-targeted regimens in the metastatic setting	Puma Patient Lynx	https://nerlynxhcp.com/access-and-support https://nerlynxhcp.com/pdf/enrollment-form.pdf 855-816-5421
		Puma Patient Lynx Commercial Copay Support Program	https://copayportal.paysign.com/enrollment/4259419922/index.html

Regeneron's Libtayo Surround Program

877-542-8296
www.libtayohcp.com/libtayo-surround

Regeneron offers the **Libtayo Surround** program to assist patients receiving Libtayo or Lynozyfic. ◆

Regeneron/Sanofi Genzyme Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Libtayo (cemiplimab-rwlc) injection	Treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in patients who are not candidates for curative surgery or radiation; adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation Treatment of patients with locally advanced or metastatic basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate First-line treatment in combination with platinum-based chemotherapy in patients with non–small cell lung cancer (NSCLC) with no *EGFR*, *ALK*, or *ROS1* aberrations and that is either metastatic or locally advanced where patients are not candidates for surgical resection or definitive chemoradiation; or as first-line single-agent treatment of patients with NSCLC whose tumors have high PD-L1 expression as determined by an FDA-approved test, with no *EGFR*, *ALK*, or *ROS1* aberrations and that is either metastatic or locally advanced where patients are not candidates for surgical resection or definitive chemoradiation	Commerical Copay Program Patient Assistance Program	www.libtayohcp.com/libtayo-surround-overview#financial-support
Lynozyfic (linvoseltamab-gcpt) injection	Treatment of adult patients with relapsed or refractory multiple myeloma who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody	Commercial Copay Program Patient Assistance Program	www.lynozyfic.com/support-and-resources/patient-support 844-746-4363

Rigel Pharmaceuticals Support Services

833-744-3562
www.gavreto-hcp.com/mnsclc/access-resources/
www.tavalissehcp.com/services-and-support

Rigel Pharmaceuticals offers the **Rigel OneCare** patient support program to assist patients receiving Gavreto or Tavalisse. ◆

Rigel Pharmaceuticals Oncology Drugs

Drugs	Indications	Patient support program	Contact information
Gavreto (pralsetinib) capsules	Treatment of adults with metastatic *RET* fusion-positive non-small cell lung cancer, as detected by an FDA-approved test; treatment of adult and pediatric patients ≥12 years of age with advanced or metastatic *RET* fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)	Free Drug Supply Copay Assistance	www.gavreto-hcp.com/mnsclc/access-resources/
Tavalisse (fostamatinib disodium hexahydrate) tablets	Treatment of thrombocytopenia in adults with chronic immune thrombocytopenia and insufficient response to previous therapies	Free Drug Supply Copay or Coinsurance Assistance Patient Assistance Program	www.rigelonecare.com/tavalisse/hcp

Sandoz One Source Support Services

www.sandoz.com/us-en/patients-services/

Sandoz, a Novartis division, offers the **Sandoz One Source** patient support program to assist patients receiving Zarxio or Ziextenzo. ◆

Sandoz Oncology Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Zarxio (filgrastim-sndz)	To decrease the incidence of febrile neutropenia in patients with nonmyeloid malignancies using myelosuppressive anticancer drugs; reduce time to neutrophil recovery and duration of fever after induction or consolidation chemotherapy in patients with acute myeloid leukemia; reduce the duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies receiving myeloablative chemotherapy followed by bone marrow transplantation; mobilize autologous hematopoietic progenitor cells; reduce the incidence and duration of sequelae of neutropenia in symptomatic patients with congenital, cyclic, or idiopathic neutropenia	Commercial Co-Pay Program	https://qv.trialcard.com/zarxio#/app/layout/home 844-726-3691
		Sandoz Patient Assistance	www.sandoz.com/us-en/patients-services/ https://portal.trialcard.com/sandozpatientassistance/
Ziextenzo (pegfilgrastim-bmez)	To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies who are receiving myelosuppressive anticancer drugs with a significant incidence of febrile neutropenia	Ziextenzo Co-Pay Program	www.ziextenzo.com/pro/access-and-reimbursement/ www.ziextenzo.com/co-pay/ 844-726-3691
		Sandoz Patient Assistance	www.sandoz.com/us-en/patients-services/ https://portal.trialcard.com/sandozpatientassistance/

Sanofi CareASSIST Patient Support Services

833-930-2273
www.sanoficareassist.com/hcp

888-847-4877
www.sanofipatientconnection.com/hcp

Sanofi offers the **CareASSIST and Patient Connection programs** to assist patients prescribed certain Sanofi medications. ◆

Sanofi Supportive Care/Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Elitek (rasburicase)	Single course of treatment for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid	Sanofi Patient Connection	www.sanofipatientconnection.com/hcp 888-847-4877
Jevtana (cabazitaxel)	Treatment of patients with metastatic castration-resistant prostate cancer, in combination with prednisone, after a docetaxel-containing regimen	Sanofi Patient Connection	www.sanofipatientconnection.com/hcp 888-847-4877
Sarclisa (isatuximab-irfc) injection	In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received ≥2 therapies including lenalidomide and a proteasome inhibitor; in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory MM who have received 1 to 3 prior lines of therapy; in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed MM who are not eligible for autologous stem cell transplant	CareASSIST	www.sanoficareassist.com/hcp 833-930-2273

Seagen Secure Support Services

855-473-2873
www.seagensecure.com/hcp/adcetris
www.seagensecure.com/hcp/tivdak
www.seagensecure.com/hcp/tukysa

Seagen offers the **Seagen Secure** patient assistance program to help patients while taking a Seagen oncology medication, including the **Commercial Out-of-Pocket Assistance Program**, the **Patient Assistance Program**, and **Oncology Access Advocates**. ◆

Seagen Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Adcetris (brentuximab vedotin)	Treatment of adult patients with untreated stage III or IV classical Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine, and dacarbazine; pediatric patients age ≥2 years with untreated high-risk classical HL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide; adults with classical HL at high risk for relapse or progression after autologous hematopoietic stem cell transplant (HSCT) consolidation; adults with classical HL, after failure of autologous HSCT, or after ≥2 multiagent chemotherapy regimens if ineligible for transplant; adults with untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphoma, in combination with cyclophosphamide, doxorubicin, and prednisone; adults with systemic anaplastic large cell lymphoma after failure of ≥1 multiagent chemotherapy regimen; adults with primary cutaneous anaplastic large cell lymphoma, or CD30-expressing mycosis fungoides after systemic therapy	Commercial Out-of-Pocket Assistance Program Patient Assistance Program Oncology Access Advocates	www.seagensecure.com/hcp/adcetris#resources 855-473-2873
Tivdak (tisotumab vedotin-tftv) for injection	Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy	Commercial Out-of-Pocket Assistance Program Patient Assistance Program Oncology Access Advocates	www.seagensecure.com/hcp/tivdak#resources
Tukysa (tucatinib) tablets	Treatment, in combination with trastuzumab and capecitabine, of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received ≥1 HER2-targeted regimen in the metastatic setting; treatment, in combination with trastuzumab, of adults with *RAS* wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy	Commercial Out-of-Pocket Assistance Program Patient Assistance Program Oncology Access Advocates	www.seagensecure.com/hcp/tukysa#resources

Secura Bio Secura Care

844-973-2872
www.securabio.com/product-information/#securacare

Secura Bio offers the **Secura Care Patient Support Program** to assist patients while taking Copiktra. ◆

Secura Bio Oncology Drug

Drug	Indication	Patient support programs	Contact information
Copiktra (duvelisib)	Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after ≥2 prior therapies	Copay Assistance Quickstart Program	www.securabio.com/product-information/#securacare 844-973-2872 www.securabio.com/forms/Secura-Care-Enrollment-Form-USCPR2213601.pdf

ServierONE Patient Support Services

800-813-5905
www.servierone.com/hcp

The **ServierONE** Patient Support Services program provides patients with financial assistance and one-on-one support when prescribed a Servier oncology product. ◆

Servier Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Asparlas (calaspargase pegol-mknl)	As a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and young adult patients (aged 1 month to 21 years) with acute lymphoblastic leukemia	Patient Assistance Program	www.servierone.com/hcp/financial-support/asparlas 800-813-5905
		ONE for ALL	www.servieroneforall.com/s/services
Oncaspar (pegaspargas)	As a component of a multiagent chemotherapeutic regimen for the treatment of pediatric and adult patients with acute lymphoblastic leukemia and hypersensitivity to native forms of L-asparaginase	Patient Financial Support	www.servierone.com/hcp/financial-support/oncaspar 800-813-5905
		ONE for ALL	www.servieroneforall.com/s/services
Tibsovo (ivosidenib) tablets	In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible *IDH1* mutation as detected by an FDA-approved test in adults aged ≥75 years, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of adult patients with relapsed or refractory AML with a susceptible *IDH1* mutation as detected by an FDA-approved test; treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an *IDH1* mutation as detected by an FDA-approved test	Copay Program QuickStart Program Patient Assistance Program	www.servierone.com/s/hcp/tibsovo www.servierone-copay.com/tibsovo 844-409-1141
		Take on CCA	www.takeoncca.com/support-and-resources www.servierone.com/hcp 800-813-5905
Voranigo (vorasidenib) tablets	Treatment of patients aged ≥12 years with grade 2 astrocytoma or oligodendroglioma with a susceptible *IDH1* or *IDH2* mutation, following surgery including biopsy, sub-total resection, or gross total resection	Copay Program QuickStart Program Patient Assistance Program	www.servierone.com/hcp/financial-support/voranigo 800-813-5905
			www.servierone-copay.com/vora 800-813-5905

Sobi's Managed Access Programmes

833-368-2663
www.sobi.com/en/managed-access

Sobi offers the **Managed Access Programmes** to provide access and reimbursement support to patients who have been prescribed a Sobi medication. ◆

Sobi Oncology Supportive Drugs

Drugs	Indications	Patient support programs	Contact information
Doptelet (avatrombopag)	Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment	Free Trial Offer Copay Assistance Program Doptelet Bridge Program Patient Assistance Program	www.doptelethcp.com/itp/access#Doptelet-Connect 833-368-2663
Vonjo (pacritinib) capsules	Treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L	Vonjo Copay Assistance Program Vonjo Patient Assistance Program Vonjo QuickStart Program Vonjo Bridge Program	www.vonjo.com/vonjo-patient-assistance-and-support-programs 888-284-3678

Spectrum Pharmaceutical's Access4Me

866-582-2737
www.access4me.com

Spectrum Pharmaceuticals offers the **Access4Me** program to provide access and reimbursement support to patients who have been prescribed Rolvedon. ◆

Spectrum Oncology Supportive Drug

Drug	Indication	Patient support programs	Contact information
Rolvedon (eflapegrastim-xnst) injection	To decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia	Bridge Program Copay Assistance Patient Assistance Program First-Cycle Patient Support	www.access4me.com/patient-support/ 866-582-2737

SpringWorks CareConnections

844-227-3755
https://springworkstxcares.com/

SpringWorks **CareConnections** provides personalized support services and resources to help patients start and stay on track with their SpringWorks medications. ◆

SpringWorks Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Gomekli (mirdametinib)	Treatment of adult and pediatric patients aged ≥2 years with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection	Commercial Copay Program Reimbursement for eligible Gomekli treatment-related costs Patient Assistance Program Quick Start Program Bridge Program	www.gomekli.com/hcp/patient-support www.springworkstxcares.com/gomekli/hcp/about/ 844-227-3755
Ogsiveo (nirogacestat)	Treatment of adult patients with progressing desmoid tumors who require systemic treatment	Commercial Copay Program Patient Assistance Program Quick Start Program Bridge Program	www.ogsiveo.com/hcp/order-access-patient-support/ www.springworkstxcares.com/ogsiveo/hcp/about/ 844-227-3755

Sun Pharma Patient Support Programs

877-636-6961
www.odomzo.com/hcp/oncology

855-984-6307
www.yonsarx.com/support

Sun Pharma offers the **Yonsa Support** program and the **Odomzo Support** program to help patients receiving these medications. ◆

Sun Pharma Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Odomzo (sonidegib)	Treatment of adults with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy	Odomzo Co-Pay Program	www.activatethecard.com/7436/ 877-636-6961
Yonsa (abiraterone acetate)	Treatment of metastatic castration-resistant prostate cancer, in combination with methylprednisolone	Yonsa Support Co-Pay Program	www.activatethecard.com/7702/# 855-984-6307

Syndax Pharmaceuticals SyndAccess

888-567-7963
https://revuforj.com/

Syndax Pharmaceuticals, through its **SyndAccess** program, offers financial support to patients receiving Revuforj. ◆

Syndax Oncology Drug

Drug	Indications	Patient support program	Contact information
Revuforj (revumenib)	Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (*KMT2A*) translocation as determined by an FDA-authorized test in adult and pediatric patients aged ≥1 year; treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (*NPM1*) mutation in adult and pediatric patients aged ≥1 year who have no satisfactory alternative treatment options	Copay Program	www.syndaccess.com/ 888-567-7963

Taiho Oncology Patient Support Services

844-824-4648
www.taihopatientsupport.com

Taiho Oncology offers the **Taiho Oncology Patient Support** program to help patients receiving Inqovi, Lonsurf, or Lytgobi. ◆

Taiho Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Inqovi (decitabine and cedazuridine) tablets	Treatment of adults with myelodysplastic syndromes, including de novo and secondary myelodysplastic syndrome with the following French-American-British subtypes: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia; and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups	Taiho Oncology Co-pay Assistance Program	www.taihooncologycopay.com 844-824-4648
Lonsurf (trifluridine and tipiracil) tablets	Treatment, alone or in combination with bevacizumab, of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF biological therapy; and if *RAS* wild-type, an anti-EGFR therapy Treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with ≥2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/*neu*-targeted therapy	Taiho Oncology Co-pay Assistance Program	www.taihooncologycopay.com 844-824-4648
Lytgobi (futibatinib) tablets	Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring *FGFR2* gene fusions or other rearrangements	Taiho Oncology Co-pay Assistance Program	www.taihooncologycopay.com 844-824-4648

Takeda Oncology Here2Assist Services

844-817-6468
www.here2assist.com/hcp/home

Takeda Oncology offers the **Here2Assist** support program to help patients who are prescribed a Takeda Oncology treatment. ◆

Takeda Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Alunbrig (brigatinib) tablets	Treatment of adult patients with *ALK*-positive metastatic non-small cell lung cancer, as detected by an FDA-approved test	Takeda Oncology Co-Pay Assistance Program	www.TakedaOncologyCopay.com www.here2assist.com/hcp/financial-assistance
		Takeda Oncology Patient Assistance Program	www.here2assist.com/hcp/financial-assistance
Iclusig (ponatinib) tablets	Treatment of adults with chronic phase chronic myeloid leukemia (CML) with resistance or intolerance to ≥2 prior kinase inhibitors; accelerated phase or blast phase CML or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) for whom no other kinase inhibitors are indicated; *T315I*-positive CML (chronic, accelerated, or blast phase) or *T315I*-positive Ph+ ALL	Takeda Oncology Co-Pay Assistance Program	www.TakedaOncologyCopay.com www.here2assist.com/hcp/financial-assistance
		Takeda Oncology Patient Assistance Program	www.here2assist.com/hcp/financial-assistance
Ninlaro (ixazomib)	In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received ≥1 prior therapy	Takeda Oncology Co-Pay Assistance Program	www.TakedaOncologyCopay.com
		Takeda Oncology Patient Assistance Program	www.here2assist.com/hcp/financial-assistance

TerSera SupportSource

844-965-2339
www.zoladexhcp.com
www.terserasupportsource.com

844-937-6356
www.xermelo.com/hcp/patient-support

TerSera Therapeutics offers the **TerSera SupportSource** program to help patients while receiving a TerSera oncology medicine by removing the financial and access barriers that patients sometimes encounter. ◆

TerSera Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Varubi (rolapitant)	Indicated in combination with other antiemetic agents for prevention of delayed nausea and vomiting in adults associated with emetogenic cancer chemotherapy, including highly emetogenic chemotherapy	Varubi Co-Pay Card	www.activatethecard.com/7774/# 844-864-3014
		Patient Assistance Program	https://documents.tersera.com/varubi/VarubiEnrollmentForm.pdf 855-686-8725
Xermelo (telotristat ethyl)	Treatment, in combination with a somatostatin analog, of carcinoid syndrome diarrhea in adults that is inadequately controlled by somatostatin analog therapy	Xermelo Co-pay Program	https://copay.xermelo.com
		Patient Assistance Program	https://documents.tersera.com/xermelo/PhysicianEnrollmentForm.pdf 844-937-6356
Zoladex (goserelin implant)	Management of localized, stage T2b-T4 (stage B2-C) prostate cancer, in combination with flutamide; palliative treatment of advanced prostate cancer; palliative treatment of advanced breast cancer in pre- and peri-menopausal women	Zoladex Co-Pay Card Zoladex Savings Program	www.activatethecard.com/7526/?# www.zoladexhcp.com/access-support/ 844-864-3014
		Patient Assistance Program	www.zoladexhcp.com/pdf/patient-assist-enroll_form.pdf www.zoladexhcp.com/access-support/ 855-686-8725

Teva Oncology Support Services

888-838-2872
www.tevausa.com/our-products/article-pages/patient-assistance-programs/

Teva Oncology offers various support programs to help patients while receiving a Teva Oncology treatment. ◆

Teva Oncology/Supportive Care Drugs

Drugs	Indications	Patient support programs	Contact information
Bendeka (bendamustine hydrochloride)	Treatment of patients with chronic lymphocytic leukemia Treatment of patients with indolent B-cell non-Hodgkin lymphoma progressing during/within 6 months of rituximab or a rituximab-containing regimen	Teva CORE	www.tevacore.com
Granix (tbo-filgrastim)	To reduce severe neutropenia duration in patients aged ≥1 month with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia	Patient Savings Program	www.granixrx.com/resources
Herzuma (trastuzumab-pkrb)	Adjuvant treatment of HER2-overexpressing node-positive or -negative breast cancer, in combination with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; in combination with docetaxel and carboplatin; or as monotherapy after multimodality anthracycline-based therapy First-line treatment of HER2-overexpressing metastatic breast cancer, in combination with paclitaxel, or as monotherapy in patients who received ≥1 chemotherapy regimen for metastatic disease Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with cisplatin and capecitabine or 5-fluorouracil, in patients who have not received previous therapy for metastatic disease	Cost Support Program	www.herzumahcp.com/support-and-resources/ www.herzuma.com/resources-and-support 888-587-3263
Truxima (rituximab-abbs)	Treatment of adults with relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent; treatment of previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; treatment of nonprogressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; treatment of previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens Treatment of previously untreated and previously treated CD20-positive chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide Treatment, in combination with methotrexate, of adults with moderately to severely active rheumatoid arthritis who have inadequate response to ≥1 tumor necrosis factor antagonist therapy Treatment of adults with granulomatosis with polyangiitis (Wegener granulomatosis) and microscopic polyangiitis, in combination with glucocorticoids	Cost Support Program	www.truximahcp.com/support-resources 888-587-3263
		Cost Support Program	www.tevacore.com/truximahcp08202025/support-resources/

UroGen Pharma UroGen Support

855-535-6986
www.jelmyto.com/hcp/access-support/support-services

UroGen Pharma offers the **UroGen Support** program to assist patients receiving Jelmyto or Zusduri. ◆

UroGen Pharma Oncology Drugs

Drugs	Indications	Patient support programs	Contact information
Jelmyto (mitomycin)	Treatment of adults with low-grade upper tract urothelial cancer	Copay Program Patient Assistance Program	www.jelmyto.com/hcp/access-support/support-services
Zusduri (mitomycin) intravesical solution	Treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer	Copay Program Patient Assistance Program	www.zusduri.com/hcp/access-and-support/support-services/

Index by Drug

Abecma (idecabtagene vicleucel) suspension for intravenous infusion 25
Abraxane (paclitaxel protein-bound particles) for injectable suspension 25
Actemra (tocilizumab) injection 39
Adcetris (brentuximab vedotin) 81
Afinitor (everolimus) tablets/**Afinitor Disperz** (everolimus tablets for oral suspension) 64
Akynzeo (netupitant and palonosetron) capsules ... 47
Akynzeo (netupitant and palonosetron) injection ... 47
Alecensa (alectinib) 39
Alimta (pemetrexed) for injection 56
Alunbrig (brigatinib) tablets 88
Amtagvi (lifileucel) 50
Aranesp (darbepoetin alfa) 11
Arzerra (ofatumumab) 64
Asparlas (calaspargase pegol-mknl) 83
Augtyro (repotrectinib) capsules 25
Avastin (bevacizumab) 39
Ayvakit (avapritinib) tablets 24
Balversa (erdafitinib) tablets 52
Bavencio (avelumab) injection 37
Bendeka (bendamustine hydrochloride) 90
Besponsa (inotuzumab ozogamicin) 71
Bizengri (zenocutuzumab-zbco) 70
Blenrep (belantamab mafodotin-blmf) 46
Blincyto (blinatumomab) 11
Bosulif (bosutinib) 71
Braftovi (encorafenib) 71
Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion 25
Brukinsa (zanubrutinib) capsules 23
Cabometyx (cabozantinib) tablets 38
Calquence (acalabrutinib) 16
Columvi (glofitamab-gxbm) injection 39
Cometriq (cabozantinib) capsules 38
Copiktra (duvelisib) 82
Cosela (trilaciclib) for injection 38
Cotellic (cobimetinib) 40
Cyramza (ramucirumab) 56
Darzalex (daratumumab) 52
Darzalex Faspro (daratumumab and hyaluronidase-fihj) 53
Datroway (datopotamab deruxtecan-dlnk) 33
Daurismo (glasdegib) 71
Defitelio (defibrotide sodium) 51
Doptelet (avatrombopag) 84
Elahere (mirvetuximab soravtansine-gynx) 48
Elitek (rasburicase) 80
Elrexfio (elranatamab-bcmm) 72
Emend capsules (aprepitant) 59
Emend for injection (fosaprepitant) 59
Emend for oral suspension (aprepitant) 59
Empliciti (elotuzumab) for injection 26
Emrelis (telisotuzumab vedotin-tllv) 10
Enhertu (fam-trastuzumab deruxtecan-nxki) 16, 33, 35
Epkinly (epcoritamab-bysp) 44
Epogen (epoetin alfa) 11
Erbitux (cetuximab) 56
Erivedge (vismodegib) 40
Erleada (apalutamide) 53
Exjade (deferasirox) 64
Faslodex (fulvestrant) 18
Fotivda (tivozanib) capsules 21
Fulphila (pegfilgrastim-jmdb) 23
Gavreto (pralsetinib) capsules 78
Gazyva (obinutuzumab) 40
Gilotrif (afatinib) 24
Gleevec (imatinib mesylate) 65
Gomekli (mirdametinib) 85
Grafapex (treosulfan) 58
Granix (tbo-filgrastim) 90
Halaven (eribulin mesylate) 36
Herceptin (trastuzumab) 40
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) injection 40

Index by Drug *(Continued)*

Hernexeos (zongertinib) 24
Herzuma (trastuzumab-pkrb) 90
Ibrance (palbociclib) 72
Ibtrozi (taletrectinib) 69
Iclusig (ponatinib) tablets 88
Idhifa (enasidenib) tablets 26
Imbruvica (ibrutinib) 76
Imdelltra (tarlatamab-dlle) 11
Imfinzi (durvalumab) 18
Imjudo (tremelimumab-actl) 19
Imlygic (talimogene laherparepvec) 11
Injectafer (ferric carboxymaltose injection) 34
Inluriyo (imlunestrant) 57
Inlyta (axitinib) 72
Inqovi (decitabine and cedazuridine) tablets 87
Inrebic (fedratinib) 26
Iressa (gefitinib) 19
Itovebi (inavolisib) 40
Jadenu (deferasirox) tablets 65
Jakafi (ruxolitinib) tablets 49
Jaypirca (pirtobrutinib) tablets 57
Jelmyto (mitomycin) 91
Jemperli (dostarlimab-gxly) injection 46
Jevtana (cabazitaxel) 80
Kadcyla (ado-trastuzumab emtansine) 40
Kanjinti (trastuzumab-anns) 11
Keytruda (pembrolizumab) 59-63
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) 63
Kimmtrak (tebentafusp-tebn) injection 47
Kisqali (ribociclib) tablets 65
Kymriah (tisagenlecleucel) 66
Kyprolis (carfilzomib) 12
Lenvima (lenvatinib) 36
Libtayo (cemiplimab-rwlc) injection 77
Lonsurf (trifluridine and tipiracil) tablets 87
Lorbrena (lorlatinib) 72
Lumakras (sotorasib) 12
Lunsumio (mosunetuzumab-axgb) injection 41
Lutathera (lutetium Lu 177 dotatate) injection for intravenous use 8
Lynozyfic (linvoseltamab-gcpt) injection 77
Lynparza (olaparib) 19-20
Lytgobi (futibatinib) tablets 87
Margenza (margetuximab-cmkb) 58
Mekinist (trametinib) 66
Mektovi (binimetinib) 72
Modeyso (dordaviprone) 51
Monjuvi (tafasitamab-cxix) injection 49
Mvasi (bevacizumab-awwb) 12-13
Mylotarg (gemtuzumab ozogamicin) 72
Nerlynx (neratinib) tablets 76
Neulasta (pegfilgrastim) 13
Neupogen (filgrastim) 13
Ninlaro (ixazomib) 88
Nivestym (filgrastim-aafi) injection 73
Noxafil (posaconazole) delayed-release tablets 63
Noxafil (posaconazole) oral suspension 63
Nplate (romiplostim) 13
Nubeqa (darolutamide) 22
Nyvepria (pegfilgrastim-apgf) 73
Odomzo (sonidegib) 86
Ogivri (trastuzumab-dkst) 23
Ogsiveo (nirogacestat) 85
Ojjaara (momelotinib) tablets 46
Oncaspar (pegaspargase) 83
Onivyde (irinotecan liposome) injection 50
Ontruzant (trastuzumab-dttb) 70
Onureg (azacitidine) tablets 26
Opdivo (nivolumab) 27-28
Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) 28-29
Opdualag (nivolumab and relatlimab-rmbw) injection 30
Padcev (enfortumab vedotin-ejfv) for injection 15
Pemazyre (pemigatinib) tablets 49

Index by Drug *(Continued)*

Perjeta (pertuzumab) 41
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) 41
Piqray (alpelisib) 66
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) ..8, 67
Polivy (polatuzumab vedotin-piiq) for injection 41
Pomalyst (pomalidomide) 30
Prolia (denosumab) 14
Promacta (eltrombopag) 67
Reblozyl (luspatercept-aamt) 30
Retevmo (selpercatinib) capsules 57
Revlimid (lenalidomide) capsules....30
Revuforj (revumenib) 86
Riabni (rituximab-arrx) 14
Rituxan (rituximab) 41
Rituxan Hycela (rituximab and hyaluronidase human) injection....42
Rolvedon (eflapegrastim-xnst) injection....84
Romvimza (vimseltinib) 36
Rozlytrek (entrectinib) 42
Rubraca (rucaparib) tablets....32
Ruxience (rituximab-pvvr) 74
Rybrevant (amivantamab-vmjw)....53
Rydapt (midostaurin) capsules....67
Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) 51
Rytelo (imetelstat) 44
Sandostatin LAR Depot (octreotide acetate for injectable suspension) 67
Sarclisa (isatuximab-irfc) injection 80
Scemblix (asciminib) 67
Somatuline Depot (lanreotide) injection....50
Sprycel (dasatinib)....31
Stivarga (regorafenib) 22
Sutent (sunitinib malate)....74
Tabrecta (capmatinib) 67
Tafinlar (dabrafenib)....68
Tagrisso (osimertinib) 20
Talvey (talquetamab-tgvs) 54
Talzenna (talazoparib) 74
Tasigna (nilotinib) 68
Tavalisse (fostamatinib disodium hexahydrate) tablets....78
Tazverik (tazemetostat) tablets....50
Tecartus (brexucabtagene autoleucel) 55
Tecentriq (atezolizumab) 42
Tecvayli (teclistamab-cqyv)....54
Tepmetko (tepotinib) tablets....37
Thalomid (thalidomide)....31
Tibsovo (ivosidenib) tablets 83
Tivdak (tisotumab vedotin-tftv)....44, 81
Trazimera (trastuzumab-qyyp) 74
Trodelvy (sacituzumab govitecan-hziy) 45
Truxima (rituximab-abbs) 90
Tukysa (tucatinib) tablets 81
Turalio (pexidartinib) capsules 34
Tykerb (lapatinib)....68
Udenyca (pegfilgrastim-cbqv) 32
Valchlor (mechlorethamine) gel 47
Vanflyta (quizartinib) 34
Varubi (rolapitant) 89
Vectibix (panitumumab) 14
Venclexta (venetoclax) 10, 43
Verzenio (abemaciclib) tablets 57
Vitrakvi (larotrectinib)....22
Vizimpro (dacomitinib)....75
Vonjo (pacritinib) capsules....84
Voranigo (vorasidenib) tablets 83
Votrient (pazopanib) 69
Vyloy (zolbetuximab-clzb) 15
Vyxeos (daunorubicin and cytarabine) liposome ..51
Welireg (belzutifan) tablets....63
Xalkori (crizotinib) 75
Xeloda (capecitabine) 43
Xermelo (telotristat ethyl) 89
Xgeva (denosumab) 14
Xofigo (radium Ra 223 dichloride) injection....22

Index by Drug *(Continued)*

Xospata (gilteritinib) tablets....15
Xpovio (selinexor)....55
Xtandi (enzalutamide) capsules....15
Yervoy (ipilimumab)....31
Yescarta (axicabtagene ciloleucel)....55
Yondelis (trabectedin)....54
Yonsa (abiraterone acetate)....86
Zarxio (filgrastim-sndz)....79
Zejula (niraparib)....46
Zelboraf (vemurafenib)....43
Zepzelca (lurbinectedin)....51
Ziextenzo (pegfilgrastim-bmez)....79
Zirabev (bevacizumab-bvzr)....75
Zoladex (goserelin implant)....89
Zusduri (mitomycin) intravesical solution....91
Zydelig (idelalisib)....45
Zykadia (ceritinib)....69
Zynlonta (loncastuximab tesirine-lpyl) for injection....10
Zynyz (retifanlimab-dlwr)....49
Zytiga (abiraterone acetate) tablets....54

Empowering people with cancer is something you do every day.

So do we.

Request a complimentary bulk subscription to distribute to your patients.

conquer-magazine.com



CONQUER
the journey informed



KEYTRUDA® (pembrolizumab) Injection 100 mg

KEYTRUDA Qlex™ pembrolizumab + berahyaluronidase alfa-pmph
Subcutaneous Injection | 165 mg + 2,000 units/mL

THE MERCK ACCESS PROGRAM (MAP)

Actor Portrayal

MAY BE ABLE TO HELP ANSWER QUESTIONS ABOUT

- Benefit investigations
- Billing and coding
- Product distribution
- Co-pay assistance for eligible patients
- The prior authorizations and appeals process
- **Referral to the Merck Patient Assistance Program for eligibility determination** (provided through the Merck Patient Assistance Program, Inc.)

CONTACT THE MERCK ACCESS PROGRAM

VISIT
merckaccessprogram-keytruda.com/keytrudaqlex/

CALL
855-257-3932,
Monday through Friday, 8 AM to 8 PM ET

MERCK

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. US-PDS-00369 11/25 **keytrudahcp.com** and **keytrudahcp.com/qlex**